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INTRODUCTION 
In The Netherlands about 7,000 new breast cancer cases are diagnosed yearly 
and about 3,000 deaths annually are caused by breast cancer. The Dutch breast 
cancer incidence and mortality rates are comparable with those of the United 
Kingdom and the United States of America, which are the highest in the world 
(Waterhouse et al, 1982; WHO, 1985). 
Though intensively studied, the etiology of breast cancer is still unclear. Many 
factors are related to the risk of primary breast cancer, such as age, a family 
history of breast cancer, nulliparity, early age of menarche, late age of 
menopause, late age of first child birth, obesity, mastopathia or a history of 
radiation exposure (Kelsey, 1979; Petrakis eia/., 1982). The absolute risk 
associated with these factors, however, is small, i.e. women with a risk factor 
are only at about 2-3 times as high a risk as compared with women without 
any risk factors. This, and the nature of some of these factors explain why no 
methods are available to reduce breast cancer incidence. 
On the other hand, several studies show a breast cancer mortality reduction 
due to early detection and early treatment of the disease. The earliest positive 
results were observed in the randomised population-based HIP-trial in Greater 
New York and published in the mid 1960s and the early 1970s (Shapiro et al, 
1966; Shapiro et al., 1972). Since then screening projects in several countries 
have been set up to further evaluate the effects of breast cancer screening by 
mammography. In The Netherlands two population-based projects started in 
Utrecht (1974) and Nijmegen (1975). Ten years later, in 1984, these projects 
reported a 30-50% breast cancer mortality reduction in the screened 
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population of women initially aged 50 years and over (Collette et al, 1984; 
Verbeek et a/., 1984). But even though it was no longer disputed that early 
detection and early treatment were beneficial and current research 
concentrates on the precise effect measure (particularly in the under-age-50 
group), some problems remained with respect to the question how early 
detection could best be achieved. To evaluate this issue, a study was started to 
assess the negative side-effects of breast cancer screening with mammography, 
using data of the Nijmegen screening programme. 
In any screening project, women and physicians will be confronted with so-
called false-positive and false-negative screening test results. A false-positive 
test (or a false-positive mammography) is defmed as the detection of a suspect 
lesion on the screening mammogram that was not confirmed as malignant. 
Conversely, some women will tum out to have breast cancer between a 
previous negative screening mammogram and the next scheduled screening 
examination, a 2-year interval in the Nijmegen programme. Some of these 
cancer cases had a false-negative test result, i.e. that although the carcinoma 
was mammographically detectable it was not detected at the screening 
examination. 
Chapter 1 gives a description of the Nijmegen programme. In this chapter the 
organisation of the programme, as well as rates of attendance, referral, 
detection and interval cancer are summarized for a 12-year period, six 
screening rounds since the programme's start in 1975. 
Chapters 2, 3 and 4 deal with the occurrence of false-positive test results. 
Chapter 2 evaluates changes in the number of false-positive test results in the 
progress of the Nijmegen programme and the question if it is possible to 
reduce this number by using information on risk factors. In Chapter 3 it is 
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studied whether women with a false-positive test-result were at higher risk for 
breast cancer when compared with women who were never referred for 
clinical examination. Since women with a false-positive test result were for 
some time exposed to the fear of their having breast cancer, an attempt is 
made in Chapter 4 to evaluate any long-term psychological distress among 
these women. 
Screening might detect breast cancer that would never have been detected in 
the non-screening situation. Chapter 5 covers the issues of overdiagnoses and 
overtreatment in a screened community. 
Chapter 6 presents the numbers of so-called interval cancers (=breast cancer 
diagnosed between a negative screening examination and the subsequent 
regular screening examination) and deals with some epidemiological, 
radiological and histological aspects of these cancers. 
Finally, in Chapter 7 an up-to-date review is given of all positive and negative 
aspects of breast cancer screening. 
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CHAPTER 1 
SCREENING FOR BREAST CANCER IN NIJMEGEN 
Report of 6 screening rounds, 1975-1986' 
PHM Peeters, ALM Verbeek, JHCL Hendriks, MJH van Bon. 
Summary 
A population-based screening programme for breast cancer was initiated in 
Nijmegen in 1975 with mammography as the only screening procedure. Up to 
January 1987, six screening rounds were carried out with a 2-year screening 
interval. Rates of attendance, referral, biopsy and detection were calculated 
and numbers of interval cancer are presented in order to give a clear view of 
what repeated screening can accomplish in a population. 
At the first screening round the attendance rate was 87% for women under 
age 50 and 83% for women aged 50-64. For women aged 65 or over the 
initial attendance rate was 40%. Rates of attendance declined in subsequent 
years. Detection rates were highest for elderly women at their first 
examination: 9.5 per 1,000 screened women. Corresponding rates were 5.6 
and 2.3 per 1,000 for women aged 50-64 and below 50 respectively. The 
1
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positive predictive value for referral was, on average, 20% for women under 
age 50 and 50% for elderly women, although a sharp increase was seen in the 
last two screening examinations for all age-groups. Predictive values for 
biopsy were higher: 30% on average for women aged under 50 and 60-70% 
for elderly women, again with a sharp increase in the last two screening 
rounds. Interval cancer rates, calculated as the number of cancers occurring 
within two years among negatively screened women at risk, showed no 
particular trend and varied between 0.9-1.3 per 1,000 woman-years after each 
screening round. Compared to screen-detected cancers, interval cancers 
occurred more frequently in younger women. In women under age 50, the 
ratio between screen-detected and interval cancer was about 1:1, while it was 
about 2:1 for elderly women. 
Introduction 
Since the trial of the Health Insurance Plan of Greater New York in 1963 
(Shapiro et at., 1966; Shapiro, 1977), several screening programmes for 
breast cancer detection have been carried out in the Western world. The 
Breast Cancer Detection and Demonstration Projects (BCDDP) were 
implemented in the United States to disseminate the techniques of early 
detection of breast cancer to both the public and the medical profession 
(Beahrs eia/., 1979; Baker, 1982). By 1975, 29 BCDDP centres had been 
established at 27 locations throughout the United States. 
In Canada, a multicentre trial started to evaluate the efficacy of 
mammography and physical examination in women aged 40-49 and of the 
independent effect of mammography in women aged 50-59 (Miller, 1984; 
Miller & Bulbrook, 1982). The study commenced in Toronto in 1980 and by 
1986 fifteen screening centres were in operation. 
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Since 1974 population screening by single-view mammography has been 
performed in an increasing number of regions in Sweden. The first projects 
started in Gävleborg county and in the urban parish of Sandviken (Lundgren, 
1979a; Lundgren & Helleberg, 1982). On the initiative of the Swedish 
National Board of Health and Welfare projects were begun in Malmö, 
Kopparberg (1977), Ostergötland (1978) and Stockholm (1981) (Andersson et 
al, 1979; Tabár & Gad, 1981; Frisell et al, 1986). 
A large population-based multi-centre study was initiated in the United 
Kingdom in 1981 by the Department of Health (UK Trial of Early Detection 
of Breast Cancer Group, 1981; Roberts et al., 1984), after pilot studies of 
feasibility had been carried out (Thomas, 1975; Chamberlain et al., 1979). In 
1987, the Forrest Committee advised the Health Ministers to establish a 
national screening programme in the United Kingdom. 
In a rural area near Florence, Italy, a population-based screening programme 
for breast cancer was started in 1970 (Palli etaL, 1986). 
In Holland, a breast cancer screening project for women aged 50-64 years was 
started in Utrecht in 1974 (de Waard et al., 1984), and for women aged 35 
years or over in Nijmegen in 1975 (Verbeek, 1985). 
From the start, results have been widely published and they all show 
favourable effects, such as a better stage distribution or a reduction in breast 
cancer mortality in the population to which a screening programme is offered 
(Baines et al, 1986; Chamberlain et al, 1984; Collette etaL, 1984; Fagerberg 
etaL, 1985; Lundgren, 1979b; Palli etaL, 1986; Seidman et al., 1987; Shapiro 
et aL, 1982; Tabár et aL, 1985; Thomas, 1975; UK Trial of Early Detection of 
Breast Cancer Group, 1988; Verbeek etaL, 1984). Although many questions 
remain to be answered, such as which age-groups benefit most (Verbeek et al., 
1985; Moskowitz & Gartside, 1982; Seidman, 1977), or which screening 
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interval is the optimum (Tabár et al, 1987), or how to maintain the quality of 
the project (Peeters et ai, 1988; Schnitt et al, 1988; Witcombe, 1988), it is 
likely that many projects will be set up in the near future. The aim of this 
study is to give an indication of figures to be expected after several years of 
screening, such as compliance rates, referral rates, breast cancer detection 
rates and number of interval cancers, based upon the Nijmegen experience. 
Subjects and methods 
In the city of Nijmegen (150,000 inhabitants) a population-based screening 
programme for breast cancer was set up in 1975. In the first screening round, 
all women born in the period 1910-1939 (aged 35-64 at that time, л = 23,000) 
were contacted by personal invitation to improve compliance. In the 
subsequent screening rounds women bom before 1910 (n = 7,700) were 
invited too. When positive results of screening became available in the 
nineteen eighties, women bom in the period 1940-1944 (n= 3,900) were also 
invited. 
The screening centre is located in the municipal health centre. Single-view 
mammography was carried out as the only screening procedure every two 
years. It was standard procedure to take a single lateral view of each breast, 
which in 1982 was changed into a mediolateral-oblique view, because this 
view showed more mammary tissue. At the same time the mammography 
equipment was replaced: the senograph fx with 0.6 mm focus was replaced by 
a senograph 500t with 0.3 mm focus. 
The films were processed immediately and studied by the radiographer. An 
extra view, in the cranio-caudal direction, of both breasts was made if one of 
the lateral projections was not good enough for evaluation because of bad 
quality, over-projection or suspicion of a lesion. The frequency of this second 
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projection varied with the experience of the radiographer and the occurrence 
of dysplasia, but it never exceeded 5% of the examinations. The next day all 
mammograms were read by the radiologist, who decided if referral was 
necessary. Referral for clinical examination was called for by the presence of 
direct signs suspect for malignancy, such as a developing or progressive 
density (a mass), and/or specific calcifications. Other reasons for referral 
were indirect signs which had developed since the previous examination, such 
as asymmetry of breast tissue, skin thickening, nipple retraction or diffuse 
lymph-oedema. 
If referral was called for, the general practitioner was informed and the 
patient requested to contact him for referral to one of the two hospitals in 
Nijmegen. Physical examination by a surgeon, and complete mammography 
(including magnified cone down views and detail-views if necessary) were 
thereafter undertaken. There was a regular meeting of a so-called Diagnostic 
Mamma-Team comprising the radiologist, pathologist and surgeon who 
decided whether further investigation was needed, e.g. a mammographie check 
after 6 months, ultrasound examination, fine-needle aspiration cytology, or 
surgical biopsy. If biopsy results proved positive, therapy was started. Lobular 
carcinoma in situ (LCIS) was not treated as cancer and therefore not counted 
as a positive screening test result. 
Since January 1975, six screening rounds have been carried out; the 7th round 
started in January 1987. Rates of attendance, referral, biopsy, detection and 
numbers of interval cancer were calculated according to age at first 
examination. 
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Results 
Compliance 
The attendance rate for women aged less than 50 years was 87% in the first 
round, and stabilized in the fourth round at 67%. For women aged 50-64 
compliance was 83% in 1975-1976, declining to 50% in the sixth round. For 
women aged 65 or over, attendance was 40% at the first invitation and 
declined to 12% in 1985-1986 (by that time these women were over age 75). 
Referral 
Referral rates were highest in the first screening round for all age-categories. 
For women aged below 50 years the referral rate was 11.3 per 1,000 screened 
women. For women aged 50-64 and those aged 65 or over, referral rates were 
14.7 and 20.0 per 1,000 women respectively. Referral rates have dropped 
during the programme. For the youngest age-group, referral rates are still 
declining, to 3.8 per 1,000 in the 6th screening round, but this rate is based on 
small number. For women over 50 years, referral rates dropped by 50% in 
the second round and have since remained almost stable. 
Biopsy and detection rate plus predictive value 
Detection rate was highest for elderly women in the first screening round: 9.5 
per 1,000 screened women over age 65. For women aged 50-64, and for those 
below 50, the respective figures were 5.6 and 2.3 per 1,000 screenees. Rates 
declined at the second examination and remained roughly stable afterwards. 
For women under age 50 they varied between 1.5 and 2.4 per 1,000, for 
women aged 50-64 the detection was between 3.8 and 6.7 per 1,000, and for 
women aged 65 or older it varied between 2.8 and 9.5 (These rates were based 
on small numbers). 
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Table 1.1. Number of invited, screened, referred and biopsied women and number of cancers 
detected at screening and in the interecreening period of 2 years 
Women under age 50. at entry 
(Birth-cohcrt 1925- 39) 
Invited 
Referred 
Biopsy 
Cancer at screening 
Interval cancer 
Ground 
11,9^9 
10,397 
117 
81 
24 
17 
Women aged 50 - 64, at entry 
(Birth cohort 1910-24) 
Invited 
Screened 
Referred 
Biopsy 
Cancer at screening 
Interval cancer 
Women aged 65 or over 
(Birth cohort<1910) 
Invited 
Soreoied 
Referred 
Biopsy 
Cancer at screening 
Interval cancer 
l 5 · round 
11,251 
9,305 
137 
102 
52 
14 
, at entry 
1 s t round 
. 
-
. 
-
-
-
(5)' 
(2) 
(4) 
(2) 
2 n d round 
11,713 
9,051 
75 
47 
" 16 
14 
2 n d round 
11,074 
7,685 
69 
49 
34 
16 
2 n d round 
7,730 
3.051 
61 
45 
29 
6 
(0) 
(3) 
(2) 
(1) 
(2) 
(0) 
3 r d round 
11,502 
8,278 
48 
38 
13 
20 
3 r d round 
10,763 
6,583 
55 
40 
24 
10 
3 r d round 
6,655 
1,768 
23 
16 
11 
2 
(2) 
(1) 
(2) 
(1) 
(0) 
(0) 
4 t h round 
11,428 
7,869 
54 
38 
12 
21 
4 t h round 
10,^32 
5,994 
49 
35 
25 
12 
4<Ь round 
6,062 
1,228 
25 
13 
11 
3 
(2) 
(1) 
(1) 
(3) 
(0) 
(0) 
5 t h round 
10,994 
7,414 
37 
17 
16 (4) 
8 (0) 
5 t h round 
9,987 
\225 
54 
4« 
35 (5) 
10 (0) 
5 t h round 
5,038 
72< 
5 
2 
2 (0) 
5 (0) 
b1*1 round 
11.14 
",442 
28 
21 
18 (4) 
5 ( 0 ) " 
6 t h round 
9,970 
4,493 
37 
33 
32 (6) 
5 ( 1 ) " 
б'
11
 round 
4,591 
^32 
7 
5 
5 (1) 
2 ( 1 ) " 
In parentheses number of intraductal cancers, included m the total number of cancers 
Number of interval Cancers up to January 1987, interval cancers occurring in 1987 and 1988 not included 
yet 
The positive predictive value of refeixal (PV+ referral) denotes the number of 
cancers among referred women. It was on average 20% for women under age 
50, although a sharp increase was seen in the fifth and sixth examinations up to 
43% and 64%. For women aged 50-64 the PV+ was about 38-51%, again with 
an increase in the last two examinations: 65% and 87%. The PV+ for women 
over age 65 was 40-58%. 
The positive predictive value of biopsy, i.e. the number of cancers among 
biopsied women, was much higher for all age-categories. It was on average 
30% for women below 50 years, with an increase up to as much as 86% in the 
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sixth screening round. The PV+ for biopsy for women aged 50-64 was 50-
70% and increased to 97% in the sixth round. It was 65-85% for women aged 
65 or over. 
Table 1 2. Rates of attendance (per 100 invited), referral, detection (per 1000 screenees), and 
positive predictive values (PV+) for referral and biopsy. 
Women under age 50, at entiy 
(Birth-cohort 1925-39) 1 s t round 
Attendance 869% 
Reffenal 11 3 
Detection 2 3 
PV+ referral 20 5% 
PV+ biopsy 29 6% 
Women aged 50 - 64, at entry 
(Birth cohort 1910 24) 1 s t round 
Attendance 82 7% 
Refferral 14 7 
Detection 5 6 
PV+ referral 38 0% 
PV+biopsy 510% 
Women aged 65 or older, at entry 
(Birth cohort<1910) lstround 
Attendance 
Refferral 
Detection 
PV+ referral 
PV+ biopsy 
2 n d round 
77 3% 
8 3 
1 8 
213% 
34 0% 
2nd round 
69 4% 
9 0 
4 4 
49 3% 
69 4% 
2 n d round 
39 5% 
20 0 
9 5 
47 5% 
64 4% 
3"1round 
72 0% 
5 8 
1 6 
27 1% 
34 2% 
З"
1
 round 
612% 
8 4 
3 8 
45 5% 
62 5% 
З«
1
 round 
26 6% 
130 
6 2 
47 8% 
68 8% 
4 t h round 
68 9% 
6 9 
1 5 
22 2% 
316% 
4 t h round 
56 9% 
8 2 
4 2 
510% 
714% 
4 , h round 
20 3% 
20 4 
9 0 
440% 
84 6% 
5 t h round 
674% 
5 0 
2 2 
43 2% 
59 3% 
5 t h round 
52 3% 
103 
6 7 
64 8% 
87 5% 
5 , h round 
14 4% 
6 9 
2 8 
6 * round 
66 7% 
3 8 
2 4 
64 3% 
85 7% 
6 * round 
501% 
7 4 
6 4 
86 5% 
96 7% 
б * round 
116% 
13 2 
9 4 
58 3%* 
100 0%* 
* 4th and 5th examination combined because of small numbers 
Interval cancer rates 
Numbers of interval cancer were too small to calculate reliable rates 
according to age, so they were calculated for all ages combined for the 
separate screening rounds. After the first screening round the interval cancer 
rate was 0.85 per 1,000 screened woman years. This rate rose to 0.99 per 
1,000 after the second screening round, when women aged over 65 years were 
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screened too. The figures for third, fourth and Fifth screening round were 
1.01, 1.27 and 0.87 per 1,000 screened woman-years respectively. 
Compared to screen-detected cancer, interval breast cancer occurred more 
frequently in the younger age-group. The ratio between screen-detected 
cancers and interval cancers for women below 50 was 1:1 on average, and 2:1 
for both age groups over 50 years. 
Discussion 
Like any other screening programme for breast cancer, the Nijmegen project 
was set up to reduce breast cancer mortality in the screened population. 
Because of the non-randomized design of the project, the result of screening 
was evaluated by means of a case-control study, conducted in 1984 and 
showing a 50% mortality reduction in the screened population (Verbeek et al, 
1984). If screening for breast cancer is that effective, overall breast cancer 
mortality in the city of Nijmegen should fall. Although the annual number of 
breast cancer deaths in Nijmegen has dropped from an average of 30 in the 
late 1970s to an average of 20-25 in the mid-1980s, the difference is too small 
to be statistically reliable. It was calculated that a new stable situation of 20 
breast cancer deaths a year cannot be expected before the second half of the 
1990s (Verbeek, 1985). 
Unfortunately, no data about stage distribution were available in this project, 
since one of the hospitals did not routinely examine axillary lymph nodes 
before 1980. Of all cancers detected at first screening examination, 21% 
showed a maximum diameter of less than 10mm, while 20% were over 20mm 
at diagnosis. Cancers detected at subsequent screening examinations were 
smaller: 33% were less than 10mm, while 20% were over 20mm. Interval 
cancers were larger: 10% were less than 10 mm, while 43% were over 20 
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mm. Only 7% of cancers in women who had never participated were less than 
10mm and 76% were over 20mm in diameter. 
Attendance was highest in the first screening round for all ages, and rates 
declined thereafter. One of the reasons may be ageing, since women grew 10 
years older and it is generally known that elderly women participate less. No 
special attempts were made to maintain a high attendance. However, except for 
age, non-attenders did not seem to be selective, since rates of breast cancer 
diagnosis in non-attenders were comparable to rates of diagnosis in women of 
a neighbouring city with no screening programme (Verbeek et al., 1984). 
The sensitivity rate of mammographie screening is often calculated as the 
number of screen-detected cancers divided by the total number of screen-
detected and interval cancers. Calculated thus, the sensitivity rate of 
mammography was highest for the oldest age-group (<50, 50-64 and 65+ 
years: 59%, 79% and 83% respectively) and declined in the following 
examinations (for the age-groups <50, 50-64 (rounds 2 to 5 combined) and 
65+ (rounds 3 to 5 combined): 48%, 71% and 71% respectively). The decline 
in sensitivity was observed earlier: from 85% to 77% in the HIP study (Smart 
& Beahrs, 1979) and from 96% to 60% in the London project (Chamberlain 
et al., 1984). It is explained by the presence of cases with a relatively long 
pre-clinical phase at the first examination and hence a larger number of 
screen-detected cases in a previously unscreened population. The Nijmegen 
study showed a corresponding drop in screening detection rates but relatively 
constant numbers of interval cancers. 
Sensitivity calculated in this way depends on the duration of the screening 
interval: the longer the interval, the lower the sensitivity rate. When the 
sensitivity rates were calculated by including only interval cancers occurring 
within one year after a previous negative screening examination, sensitivity 
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rates for women under age 50 for round 1 and rounds 2-5 became 84% and 
62% respectively. These figures were 93% and 84% for women aged 50-64, 
and 89% and 88% for women aged 65 or over. Furthermore it was pointed 
out by Day (1985) that this estimate is quite inaccurate, because a certain 
proportion of the interval cancer cases will have a pre-clinical detectable phase 
beginning after the previous screening examination. 
Specificity is defined by the number of women with negative results expressed 
as a proportion of all women not diagnosed as having breast cancer before the 
next screening examination is due. Specificity at the first examination was 
high: 99.1% for the age-groups below 50 and 50-64, and 98.9% for women 
aged 65 or over. In the subsequent rounds (2-5 combined) specificity rates 
were 99.5% and 99.6% for the age-groups below 50 and 50-64 respectively, 
and (3-5 combined) 99.2% for women aged 65+. This improvement may be 
due to increasing experience of the screening staff in ascertaining the degree 
of abnormality necessitating referral and to an increasing quality of 
performance. 
The predictive value depends on sensitivity and specificity of mammography 
and on the prevalence of the disease. Besides the increased difficulty of 
interpreting mammograms in younger women due to dense breast 
parenchyma, the low PV+ in the under 50 age-group was most probably a 
consequence of the lower presence of breast cancer in younger women. In the 
fifth and sixth examinations there was a sharp increase in PV+ for all age-
groups. This was probably due to the change in equipment and viewing 
technique (Peelers eia/., 1987). It was not the consequence of a change in 
referral decision, which would result in high numbers of interval cancers: the 
observed numbers of interval cancers after the fifth and sixth screening 
rounds did not exceed those observed after screening in the preceding rounds. 
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Breast cancer detection rates for women under age 65 showed a decline until 
the fourth round, but rose again afterwards. Detection in women over age 65 
did not show a decline. We also investigated whether there was a fall in breast 
cancer detection in women who participated regularly, i.e. every two years. In 
none of the age-groups there was a fall, so it seems that new breast cancers 
keep on developing, even in elderly women and despite repeated screening. 
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CHAPTER 2 
THE PREDICTIVE VALUE OF POSITIVE TEST RESULTS IN 
SCREENING FOR BREAST CANCER BY MAMMOGRAPHY IN THE 
NIJMEGEN PROGRAMME' 
PHM Peelers, ALM Verbeek, JHCL Hendriks, R Holland, 
M Mravunac. 
Summary 
After 10 years of screening for breast cancer by mammography in Nijmegen, 
the predictive value of positive screening results (PV+) was evaluated. The 
percentage of women with breast cancer in the group of referred women 
(PV+) for women under age 50 was 16-26%, regardless of the number of 
screening examinations they had. The percentage of women with breast cancer 
in the group of women who were biopsied was 25-40%, regardless of the 
number of examinations. For women aged 50 and over the predictive value 
was 34-57%, and 58-90% respectively. It was further evaluated whether 
characteristics such as age, Quételet index, parity, and Wolfe-classification 
could be used to increase the PV+ in women who were identified as positive 
1
 Br J Cancer 1987; 56, 667 
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by mammography. A logistic regression model analysis showed that true-
positive and false-positive cases differ significantly only in terms of age and 
breast complaints. Although the model had a good fit, it could not be used to 
distinguish false-positive from true-positive test results. 
Introduction 
Since 1975 five screening rounds have been carried out in a non-randomised 
screening project with biennial mammography in the city of Nijmegen. The 
results of breast cancer screening projects such as the HIP-trial in the United 
States (Shapiro et al., 1982), the DOM-project in Utrecht (Collette et al, 
1984), the Nijmegen screening project (Verbeek et al., 1984) and the Swedish 
trials (Tabár et al., 1985) show a considerable reduction of breast cancer 
mortality. But even though it is no longer disputed that early detection and 
early treatment are beneficial, some unsolved problems remain with respect to 
how they can best be achieved. One of the problems inherent to screening is 
that a number of women who have been identified by mammography as 
suspect for malignancy will turn out to be false-positive cases at an additional 
clinical examination. One of these additional procedures is mammographie 
localization of the lesion and biopsy. Undergoing preoperative mammographie 
localization and surgical biopsy is an emotional strain on the patient; the 
procedures are expensive and, like any invasive procedure, they are not 
without risks of complication. 
It is important therefore to aim for a screening test that yields as few false-
positive test results as possible. When the Nijmegen project had run for 10 
years, and when new mammographical equipment and a different viewing 
technique had been used for some years, it was decided to evaluate the positive 
predictive value (PV+), which is the percentage of women with breast cancer 
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in the total group of referred women. Attempts were made to reduce the 
number of false-positive screening mammograms before proceeding to 
excision biopsy. To do so, it was ascertained whether the PV+ of the screening 
test could be increased by using certain epidemiologic characteristics of the 
referred women in addition to the mammographie data without increasing the 
number of false-negative test results. 
Subjects and methods 
All data came from the Nijmegen (150,000 inhabitants) programme. This 
population-based project started in January 1975. Single view mammography 
was carried out as the only screening examination every 2 years. It was 
standard procedure to make a single lateral view of both breasts, which, in 
1982, was changed into a medio-lateral-oblique view. At the same time the 
mammographie apparatus was replaced: the senographe fx with 0.6 mm focus 
was replaced by a senographe 500t with 0.3 mm focus. 
In the first screening round women bom in the period 1910- 1939 (л = 
23,000) were invited. In the subsequent screening rounds women bom before 
1910 (n = 7,700) were invited too; in the fifth screening round the cohort of 
women bom in the period 1940-1944 (я= 3,900) was invited. 
All mammograms are read by the radiologist, who decides if referral is 
necessary. If so, the general practitioner is informed and the patient requested 
to contact him for referral to hospital. Physical examination by a surgeon and 
complete mammography (including magnified cone down views and 
detailviews if necessary) are thereafter undertaken. There is mutual 
consultation between the radiologist, pathologist and surgeon concerned who 
decide if any further investigation is called for, e.g. a mammographie check 
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after 6 months, ultrasound examination, fine-needle aspiration cytology, or 
surgical biopsy. If biopsy results prove positive, the actual treatment is started. 
In 5 screening rounds 801 women were referred to hospital to be clinically 
examined after a single view at the screening centre: breast cancer was his-
tologically confirmed in 302 of them within 1 year of referral. Ten women 
were not classified because no physical and histological examination was done: 
six of them were 78 or older; three of them refused clinical examination; and 
one was not classified because of delay in diagnostic procedure of more than 
one year. One of the women who initially refused examination had a biopsy 4 
years after referral, which revealed cancer. Of the remaining 9 women, 2 
have moved away and 3 died (as in January 1986). The remaining 4 are still 
alive without breast cancer, according to the Nijmegen breast cancer registry. 
The 489 women left were classified false-positive, which means no breast 
cancer was diagnosed within one year of referral. 
Women with a false-positive test result were compared with those with a true-
positive result in terms of a number of characteristics. Those included in this 
survey are listed in table 2.3. They were obtained through blank forms which 
the women were asked to fill in prior to the screening examination. The 
characteristic 'breast complaints' included pain not related to menses, tumours 
in breast or axilla, changes in skin or nipple secretion. The mammograms of 
the breast contralateral to those that precipitated referral, were classified 
according to the Wolfe classification into N1, PI, P2, DY breast parenchymal 
patterns (Wolfe, 1976). The classification was applied to the contralateral 
breast to avoid information bias. The aim was to detect any characteristics that 
showed significant differences in the two groups of true-positive and false-
positive cases and to see if they could be used to distinguish true-positive from 
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false-positive cases at a stage where mammography identified all of them as 
positive. 
Relative risks were calculated by the Odds Ratio approximation for each of the 
characteristics and a logistic regression model was used for adjustment; the 
regression coefficients were estimated by maximum likelihood (Breslow & 
Day, 1980). 
Results. 
Table 2.1 shows the predictive value positive (PV+), which is defined as the 
probability of having breast cancer given an initially positive mammogram. 
In the screening period the PV+ increased from 29.8% in the first screening 
round in 1975/76, to 53.8% in the fifth screening round in 1983/84. 
Table 2.1. Distribution of referred women according to screening result and screening round 
Test result Round 1 Round 2 Round 3 Round 4 Round 5 Total 
1975/76 1977Л8 1979/80 1981/82 1983/84 
True-positive 
False-positive 
Rcferred-total 
Predictive value 
75 
177 
252 
29.8% 
75 
116 
191 
39.3% 
48 
73 
121 
39.7% 
47 
74 
121 
38.8% 
57 
49 
106 
53.8% 
302 
489 
791 
38.2% 
It is possible that these crude positive predictive values are influenced by two 
factors, viz. the number of previous screening examinations at the time of 
referral and age. If mammograms from previous screening examinations are 
available, the radiologist is more likely to notice suspect mammographical 
changes when he has to decide whether or not to refer the patient. Age is 
another important factor since it is generally known that many women under 
age 50 have a dense parenchymal breast pattern, and on a mammogram, this 
pattern is more likely to mask a developing cancer than a fatty parenchymal 
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breast pattern. Because Table 2.1 contains a mixture of first (prevalence) 
screens and consecutive (incidence) screens, the PV+ in Table 2.2 was 
calculated for regular attenders only. It shows the number of screened women, 
referrals, biopsies and true-positives. 
Table 2.2. Screening results according to number of examinations and age at examination 
(for regular attenders) 
a} Women under age 50 
Screened 
Referred 
Biopsy 
True-positive 
PV+ (ref.) 
PV+ (biop) 
Specificity 
l5'exam 
12,893 
129 
84 
27 
20,9 
32.1 
99.9 
b) Women aged 50 or over 
Screened 
Referred 
Biopsy 
True-positive 
PV+ (ref.) 
PV+ (biop.) 
Specificity 
I s t exam 
13,695 
228 
172 
100 
43.9 
58.1 
99.8 
2 n d exam 
6,944 
56 
36 
9 
16.1 
25.0 
99.9 
2 n d exam 
10,907 
92 
62 
41 
44.6 
66.2 
99.8 
3«! 
3rd 
exam 
4,894 
31 
22 
8 
25.8 
36.4 
99.8 
exam 
9,204 
73 
42 
30 
47.1 
71.4 
99.8 
4th 
4th 
exam 
3,439 
27 
21 
7 
25.9 
33.3 
99.7 
exam 
8,140 
53 
24 
18 
34.0 
75.0 
99.8 
5th 
5th 
exam 
2,241 
10 
5 
2 
20.0 
40.0 
99.9 
exam 
6,892 
49 
31 
28 
57.1 
90.0 
99.8 
Total 
253 
168 
53 
20.9 
31.5 
-
Total 
495 
331 
217 
43.8 
65.5 
-
'Number of examinations' does not necessarily correspond to 'round number' in 
table 2.1, e.g., a woman may have her first examination in 198V84, round 5. 
The PV+ is given according to referral and biopsy, for each number of 
examinations and stratified for two age-groups. Women under age 50 at the 
time of referral have a PV+ of 16-26%, regardless of the number of 
examinations. There was no significant trend (Attest for linear trend in 
proportions: X2= 0.26, df = 1 ρ = 0.62) towards a higher PV+ for higher 
numbers of screening examinations. The linear trend for PV+ for biopsies was 
not significant either: A?= 0.13, p= 0.73. 
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For women aged 50 or over at referral, the PV+ at the first screening 
examination was 43.9%; for those referred at the fifth examination the PV+ 
was 57.1%. Again there was no significant trend towards a higher PV+ for 
higher numbers of examinations (Λ2= 0.22 , df = 1 ρ = 0.65). Now the linear 
trend for biopsies turned out to be statistically significant (X2~ 13.78, p< 
0.005). 
Table 2.3 presents a comparison of all true-positive and false-positive cases in 
relation to 15 characteristics. The association between a certain characteristic 
and a true-positive test result is expressed in terms of relative risk estimates. 
For example (see Table 2.3) 21.2% of the women under 50 at referral turn 
out to be true-positive while 46.7% of the women aged 50 or older at referral 
are true-positive. A woman aged 50 or older at referral will have a relative 
risk of 3.25 of having breast cancer compared with a woman who is less than 
50 at referral. 
The characteristics of age, Quételet index, menopause, Wolfe-classification, 
and breast complaints yield relative risks that differ significantly from unity. 
Because some of the characteristics are interdependent, the data were analysed 
in a logistic regression model, including all above mentioned variables, in 
order to extract the relevance of each separate characteristic. Only the 
variables of age and breast complaints yielded significant regression 
coefficients: the regression coefficient for the continuous variable of age 
(year) was 0,0606 and for breast complaints 0.8398 (l^yes, 0=no). A non-
significant result was estimated by a A?goodness of fit ρ = 0.54, which implies 
a model that is not in contradiction with the data. To check whether this well-
fitting model could be used to distinguish true-positive from false-positive 
mammographie results, the logistic model was applied to the data on age and 
breast complaints for each individual: the chance for each woman to 
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Table 2 3 Relative Risks of being classified true-positive after referral, for 15 charaaeristics 
Charactenstic 
Age at ref rami 
Quételet index 
k g m 2 
Marital status 
Panty 
Age at first child 
brth 
Breast feeding 
Age at menarche 
Regular menses 
Menopause 
Age at menopause 
Familial breast 
cancer 
Oral conttaceptive 
use 
Breast complaints 
Breast aberrations 
in history^ 
Wolfe classification 
Risk group 
250 
46 7% 
г25 
43 0% 
Never nraned 
38 5% 
0 Child 
31 3% 
225 
37 9% 
Never 
33 3% 
215 
32 5% 
No 
30 9% 
Yes 
46 0% 
250 
47 9% 
Yes 
4 3 4 % 
Ever 
30 2% 
Yes 
53 6% 
Yes 
36 1% 
Nl+Pl 
44 1% 
Reference grtep 
<50 
212% 
<25 
313% 
<Ev«r)mained 
38 1% 
¡Ί Child 
35 8% 
<25 
30 7% 
Ever 
36 2% 
<I5 
36 0% 
Yes 
35 4% 
No 
26 0% 
<50 
4 1 2 % 
No 
37 2% 
Never 
36 8% 
No 
36 6% 
No 
38 5% 
P2+DY 
32.4% 
Relative risk 
(estimated as 
Odds ratio) 
3 25 
165 
102 
0 82 
138 
0 89 
0 86 
0 82 
2 42 
1 31 
130 
0 74 
2 0 0 
0 98 
165 
P-value 
(estimated by 
association) 
p=0 0001 
p=0 0009 
(missing 13) 
p=09320 
p=0 2809 
(missing 117) ' 
p-01145 
(missinglW1 
(NR2 179) 
p-06344 
(missing 117) ' 
(NR2 179) 
p-0 3946 
(missing 147) ! 
p=0 5067 
(missing 148) ' 
ρ=0 0001 
(missing 30) 
p-0 1775 
(missing 170)1 
(NR 1250) 
p=01947 
(missing 3) 
p=01400 
(missing 139)1 
p=00055 
(missing 4) 
p=0 6114 
(missing 4) 
p=0 0007 
(missing 1) 
The great number of missing data are due to the introduction in the second screening round of new blank forms, 
which excluded these questions, 2Not relevant for women without children, •'Not relevant for premenopausal 
women, ''Aberrations operation, mastitis, cyste or radiation in history. 
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be true positive was estimated by the model. Next, these chance rates were 
stratified into 8 chance groups (0.1-0.2, 0.2-0.3 0.8-0.9) and within each 
chance group the observed number of true-positive cases was compared with 
the observed number of false-positive cases. Figure 2.1 shows these numbers. 
Number of cases 
with a false-positive 
test result 
Number of cases 
with a true-positive 
test.result 
161b 
120 
80-
40-
0-
І0-
68 
! 
1 
-.1 
16? 
Ή 
! 
1 
.2 
10 
99 
75 
-.3>-.4;-.5 
—1 
51 
-.6 
22 
-.7 
28 
3 
9 
2 
ι — 
5 1 
80~j 
55 56 
Figure 2.1. Distribution of the 787 tme-positive and false-positive test result cases according to 
chance rates, predicted by the model: Pr= l/(l+exp(-(4.005 + О.ОбОбхі + 0.8398x2 ))) 
Pr = chance of having a true-positive test result 
xj * age at referral X2 = breast complaints (0=no, 1 =yes) 
No marked line can be drawn to distinguish false-positive from true-positive 
results, without a substantial loss of true-positive test results as a result of 
distributional overlap.If, for example, a line is drawn at 0.2 percent this 
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means that women with a chance of more than 0.2 (predicted by the model on 
the basis of their age and complaints) would be referred for biopsy, whereas 
women with a chance lower than 0.2 would not. According to figure 2.1, 68 
unnecessary biopsies (68/489 = 14%) would be prevented at the cost of 10 
cancers (10/301 = 3%). This model, therefore, cannot be used in addition to 
mammographie results to distinguish false-positive from true-positive cases. 
Discussion 
The PV+ for women under the age 50 is half the PV+ for women aged 50 or 
over. Since the PV+ is a function of the sensitivity and the specificity of the 
test and the prevalence of breast cancer in the screened population, we have to 
look for an explanation of this difference in these parameters. The specificity 
rates in both age groups are very high and almost the same, viz. over 99%, 
but both the sensitivity of the test and the prevalence of breast cancer are 
lower for women under age 50 compared with women of 50 or older 
(Hendriks, 1982; Verbeek, 1985). The sensitivity rates of the test, based on the 
occurrence rate of interval cancer in a 2-year observation period, are 45-60% 
for women under 50 but 60-80% for the older age group. Some of the 
interval cancers of the breast, however, may well have been non-existent at the 
time of this previous examination and may have grown rapidly. 
There are some indications that in women under the age of 50 a more 
aggressive kind of breast cancer occurs with a faster growth rate (Strauch 
Meyer eia/., 1984). If this is true a relatively great proportion of the interval 
cancers in this young age group will be newly developed cancers, and 
consequently the above mentioned sensitivity rate of 45-60% would be too 
low. If the sensitivity and specificity rates are equal in both age groups, then 
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the lower PV+ for women under 50 could only be the result of a lower 
prevalence of breast cancer in this age group. 
In Table 2.1 an increase in PV+ is noticeable m round 5 It could be argued 
that this increase was influenced by the use of a new mammography apparatus 
in 1981. The PV+ for women under age 50 at referral did not change signifi­
cantly: before 1982 the PV+ was 19.4% (43/222) on average, and after the 
replacement 31.0% (13/42); p= 0.09. For women aged 50 or over the PV+ 
was 43.7% (180/412) on average before 1982, and after it was 57 4% 
(66/115); ρ < 0.01. However, a logistic regression analysis with "yes/no 
referred via new apparatus" in the multivariate model, age included, did not 
yield a statistically significant result 
The PV+ in Nijmegen is high compared with other PV+ rates in the literature. 
In the HIP-study (Shapiro et ai., 1966) 111 women age 40-64 were referred to 
a surgeon at their first examination with mammography only. Twelve were 
diagnosed as having breast cancer (PV+ « 11%). Later reports on the HIP 
study show about a 20% biopsy positive rate for mammography. In the 
BCDDP projects a PV+ rate of 10-15% was estimated for women aged 35-74, 
who were referred for surgery (Baker, 1982). The Guildford Screening 
Project in England (Thomas et a/., 1983) invited women aged 45-64. In the 
first screening round the PV+ for surgical examination was 27.4% and the 
PV+ for biopsies was 36.1%. In a screening service in London (Chamberlain 
et al., 1984) the PV+ for biopsies was low and decreased in the consecutive 
screening rounds from 14 to 5%, which could be the consequence of lower 
breast cancer prevalence (screening was conducted after 1/2 a year, 1 year and 
2 years). In 1974 a screening project for women older than 40 was started in 
Sandviken, a city in Sweden (Andersson eia/., 1979). In the third screening 
round in 1980 the PV+ for clinical examination for women under age 50 was 
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37.5%. For women aged 50 or older the PV+ was 60.0%. Biopsy was 
performed in 27 women, 21 of whom proved to have breast cancer: the PV+ 
for biopsies was 78%. In 1976 a breast cancer screening project was started 
for women aged 50-69 in Malmö, Sweden (Lundgren & Helleberg, 1982). 
After a complete mammographie examination 211 women were referred for 
clinical examination: 45% proved to have breast cancer. In Kopparberg, 
another county in Sweden, a screening project started in 1977 (Tabár & Gad, 
1981). Up to 1980, 1649 women, aged 39 or over, were referred for detailed 
mammographie examination and 362 underwent a biopsy. Cancer was 
diagnosed in 235 of them. The PV+ for referral was 14.3%, and the PV+ for 
biopsies was 65%. The DOM-project in Utrecht (de Waard et al, 1984) 
estimated a PV+ of 40-57% for biopsies for women aged 50-64 in all 
screening rounds. 
The various PV+ rates described in the literature are difficult to compare. The 
prevalence of breast cancer varies geographically and with age. Moreover, in 
some instances different screening intervals are used. Also different screening 
tests are used, e.g. some including physical examination as well. Viewing 
technique and mammographical equipment as well as experience and 
knowledge may vary with each project. In the U.S. a more aggressive referral 
procedure maintains a high sensitivity, most likely at the expense of specificity 
and PV+. The result is that only 1 out of 10 or even 1 out of 20 women who 
undergo biopsy will prove to have breast cancer (Hall, 1986; Moskowitz & 
Gartside, 1982). 
Another problem in comparing PV+ is the difference in referral procedures 
(Rombach, 1983). The percentage of women with breast cancer among 
referred women can be estimated at various stages in the general procedure: 
after single medio-lateral-oblique view, complete mammography, clinical 
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examination, or surgical biopsy. The results presented in Table 2.2, for 
instance, show different findings depending on whether the PV+ estimation is 
based on the numbers of women who were referred after single medio-lateral-
oblique view or on that of women who had biopsy. 
The increase in the biopsy PV+ in round five is large. As a consequence of the 
high PV+ the first results from the Nijmegen cancer registry show no high 
interval cancer rate after round five. 
Women with true-positive and false-positive test results differ significantly in 
age and breast complaints. No difference was found in the prevalence of 
familial breast cancer, which could be due to the fact that the radiologist may 
already have considered this characteristic when he decided whether or not to 
refer the woman in case of hesitation. Women who have breast complaints at 
the time of an examination have, when referred, twice as high a chance of 
turning out true-positive cases as women without complaints do. One could 
argue that the screening examination came too late for these women since 
screening is supposed to detect breast cancer in an asymptomatic stage of the 
disease. Relatively few women, however, only 8% of the screened population, 
answered the question on breast complaints in the affirmative. 
Although the groups of true-positive and false-positive cases differ 
significantly in age and breast complaints, these characteristics cannot be used 
to distinguish the two groups from each other as is shown in Figure 2.1, i.e., 
the specificity, which is very high as it is in Nijmegen, cannot be increased any 
further by using the investigated characteristics in addition to mammographie 
results. 
One could promote a more gradual referral procedure, where women contact 
a surgeon only in the last resort after a complete mammographie examination. 
In the first and second screening rounds in Nijmegen 23% of all women 
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referred for clinical examination only received complete mammography, 
showing no evidence of breast cancer after their referral; in the fifth 
screening round 16% did. This means that 16-23% of all referred women 
would not have contacted a surgeon in the gradual referral procedure where 
complete mammography would be performed after a suspect single oblique 
view. This procedure would be less of a strain on the patient and less 
expensive as well. One could then aim for a higher sensitivity of 
mammography for women under age 50, at the expense of specificity. Perhaps 
the lower specificity of the mammographie test in the gradual referral 
procedure could be improved by the use of some specific characteristics, in 
addition to mammographie results, in order to increase the overall specificity. 
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CHAPTER 3 
BREAST CANCER RISK FOR WOMEN WITH 
A FALSE POSITIVE SCREENING TEST' 
PHM Peeters, M Mravunac, JHCL Hendriks, 
ALM Verbeek, R Holland, GP Vooijs. 
The results of breast cancer screening projects such as the HIP-trial in New 
York (Shapiro et al, 1982), the DOM-project in Utrecht (Collette et al., 
1984), the Nijmegen screening project (Verbeek et al., 1984), the Swedish 
trial (Tabár et al., 1985) and the screening programme in Florence (Palli et 
al., 1986) show a considerable reduction of breast cancer mortality. But even 
though it is no longer disputed that early detection and early treatment lower 
the mortality of breast cancer, some problems remain to be solved. One of the 
problems inherent to screening is that a number of women who have been 
identified by mammography as suspect for having malignant lesions will tum 
out to be false-positive cases at additional examinations (Peeters et a/, 1987). 
A cohort study was conducted to find out whether a false-positive screening 
test result itself could be a risk factor for developing breast cancer. Women 
1
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were recruited from the population-based screening project. This project 
started in January 1975 with biennial mammography as the only screening 
examination. The first screening round was conducted in 1975/1976 among 
women born in the period 1910-1939 (n = 23,000). In the subsequent 
screening rounds women bom before 1910 were invited too; in the fifth 
screening round in 1983/84 the birth cohort 1940-1944 was invited. All 
mammograms are read by the radiologist, who decides if referral is necessary. 
Referral for clinical examination was called for after the presence had been 
established of direct signs suspect for malignancy such as, e.g., a developing 
or progressive density (a mass), and/or specific calcifications. Other reasons 
for referral were indirect signs such as asymmetry of breast tissue or skin 
thickening, nipple retraction or diffuse lymphoedema developed since the 
previous screening examination. In five screening rounds a total number of 
801 women were referred to hospital to be clinically examined after a single 
view mammography at the screening centre. Those referrals with a diagnosis 
of breast cancer within one year after referral were classified as women with 
a true-positive screening result. Breast cancer was diagnosed in 302 of the 
referrals within 1 year after referral. Nine women were not classified. They 
never passed the general practitioner for various reasons: six of them were of 
old age (78 or over); three of them refused clinical examination. Of the 
remaining 490 referred women 28 were lost to follow-up because they had 
moved outside the area or had died within one year after referral. In this way 
462 women were classified as having a false-positive test result, i.e. although 
suspect lesions were seen at the mammographie screening examination, no 
breast cancer was diagnosed within one year after referral. The women 
eligible for this study of false-positive screening results were referred between 
January 1975 through March 1984 during one of the five screening rounds. 
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March 1, 1985 was set as the date line to register whether and if so, when 
breast cancer was diagnosed during the intermediate follow-up period, starting 
1 year after referral. The follow-up period for each individual was computed 
in person months (Kleinbaum eia/., 1982). As a reference group a sample was 
taken of all women who had never been referred. Because the 462 women 
with a false-positive test result were referred in different screening rounds, 
the reference group was stratified accordingly on screening round and age. 
Analogously to women with a false-positive screening test, all women who 
developed breast cancer within one year after their screening examination 
were not enrolled into the reference group. To increase statistical efficiency a 
1:4 sample was taken, resulting in a reference group of 1,865 women with a 
true-negative test result. Breast cancers occurring in both groups were 
histologically confirmed. 
As was expected because of the design of the study, the distribution of age and 
follow-up time were similar in both groups. The mean age was 54.0 years for 
women with a false-positive test result, and 53.8 years for true-negatives. The 
mean follow-up time for women with a false-positive test result was 62.8 
months, compared with 64.0 months for the reference group. Sixteen breast 
cancer cases occurred among the group with a false-positive result in a total 
follow-up time of 28,811 months. The reference group had a total follow-up 
time of 117,604 months, during which 24 breast cancer cases were diagnosed. 
(See Table 3.1). 
It can be concluded from Table 3.1 that the incidence rate for women with a 
false-positive test result was 0.56 per 1,000 months, which is significantly 
higher (p = 0.0006) than the incidence rate of 0.20 per 1,000 months in the 
reference group. 
40 Breast cancer risk 
Table 3.1. Occurrence of" breast cancer in women with a false positive screening test, and in 
women of the reference group 
Women with false-positive Reference 
screening result group 
Number of cancers 16 24 
Follow-up 8,811 117,604 
time in months 
Incidence per 0,56 0.20 
1000 months 
Value of the Z-statistic is 3.23; p= 0.0006. 
Next, the distribution of age and follow-up time of the breast cancer cases in 
both groups were compared. Women who developed breast cancer after a 
previous false-positive test result were older when compared with women who 
developed breast cancer in the reference group (94% were 50 years or older, 
compared to 79% in the reference group). They also showed a shorter follow-
up time. Sixty-three percent turned out to have breast cancer within two years 
after the previous false-positive test result, while only 37% developed breast 
cancer in the reference group. These findings were not statistically 
significant. The histological pattern of the carcinomas is presented in Table 
3.2. 
Revision of all radiological, clinical, cytological and histological data of the 
cancer cases was performed in order to clarify the observed higher incidence 
in the false-positive group (see Table З.1.). In one case additional clinical 
mammography did not confirm the original diagnosis and the patient had been 
discharged. In 6 of the 16 cases the mammographically detected lesion was not 
included in biopsy specimen. This can be explained by the lack of routine 
specimen X-ray of biopsies (Holland et al, 1985) in the early years of the 
screening programme or by poor radiologic localisation due to small diameter 
Breast cancer risk 41 
and/or deep situation of the tumour and/or density of the breast. Some time 
lapsed before radiological tests and clinical examination were carried out. In 
three cases the suspect lesion was removed by biopsy, but not recognised as 
malignant on histological examination. Two of these lesions happened to be of 
a special type of ductal carcinoma in situ, e.g. micropapillary intraductal 
carcinoma. The third one, a minimal tubular carcinoma, was not included in 
the paraffin bloc, but was present unrecognised in the formalin jar. Twice a 
delay of more than one year occurred, because of a delay in referral by the 
general practitioner. 
Table 3.2. Distribution of histological pattern of tumours diagnosed in women with a false-
positive screening test and in women of the reference group 
Histological 
pattern 
Ductal carcinoma 
in situ 
Ductal carcinoma 
invasive 
Lobular carcinoma 
in situ 
Lobular carcinoma 
invasive 
Tubular carcinoma 
Total 
Cases in false 
positive group 
2 
7 
1 
1 
5 
16 
Cases in the 
reference group 
-
18 
-
3 
3 
24 
The results of the revision show that in 12 of the 16 cases breast cancer was 
present at the time of referral. Had all of these 12 women been worked up in 
the proper manner, all of them would have been diagnosed and dealt with in 
time considerably shorter than one year. Analysis of the remaining 4 cases 
showed that the mammographie lesion which initially necessitated referral was 
not the same as the cancer which developed later on. The occurrence of just 4 
breast cancer cases in women with a false-positive screening test involving a 
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total follow-up time of 28,503 months yields an incidence rate of 0.14 per 
1000 months, which does not differ significantly (p= 0.76) from the incidence 
rate for women of the reference group. 
The aim of this study was to find out whether a false-positive screening result 
is a risk indicator for developing breast cancer. In our analysis the study 
population consisted of women with a history of a false-positive screening 
result: although they were referred because of suspect mammographical signs, 
no malignancy was diagnosed within one year after referral. Mammographical 
lesions known to be associated with benign breast disease, such as cysts or 
fibroadenoma, are no reason for referral in the screening programme for 
early detection of breast cancer as long as there are no complaints or 
mammographical signs suspect for cancer! Nor is a false-positive referral 
identical to histologically proven benign disease. Thirty per cent of the 462 
women falsely referred never even had a biopsy. The purpose of this study 
was not to arrive at any conclusions about breast cancer risk in women with 
benign breast diseases (Peterson & Williams, 1980; Moskowitz eia7, 1980; 
Webber & Boyd., 1986), but about the risk of breast cancer in women with a 
false-positive screening result. This risk was computed to be 2.7 times as high 
as that in a reference group of women who have been screened, but never 
referred because of an abnormality. After revision, the apparently increased 
risk disappeared. To avoid the pitfalls inherent to the diagnostic procedure of 
asymptomatic women referred from the screening programme, regular 
meetings should be held by the diagnostic team including the radiologist, the 
surgeon and the pathologist. It is also mandatoiy to follow carefully designed 
protocols in the diagnostic procedure. It should be borne in mind, however, 
that when a new screening programme is launched, a lack of experience in 
reading and judging screen-detected lesions will 'inevitably manifest itself. 
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Therefore radiologists, pathologists and surgeons should be trained for the 
specific requirements of diagnosis in a screening setting (Tabár & Dean, 
1987). 
After revision the incidence rate in the false-positive group (0.14 per 1,000 
months) turned out to be somewhat lower compared with the reference group 
(0.20 per 1,000 months). One possible explanation could be that some women 
of the reference group were classified as not having cancer at the screening 
examination, while they in fact already had cancer. Indeed, revision of the 
mammograms showed that in one patient breast cancer was present at the time 
of examination and in two others the location of the breast cancer which 
developed later on was not represented on the screening mammogram. 
The follow-up time was on average 5 years for both groups. This may be too 
short to find any increase in risk. So far, however, no evidence has been found 
for any increased risk for women who have had a false-positive screening test, 
if they are very carefully examined. Even for women who had a follow-up 
time of more than 8 years, (20% of our study population), no increased risk 
was observed either. 
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CHAPTER 4 
DISTRESS AMONG REFERRED WOMEN WITHOUT A DIAGNOSIS OF 
BREAST CANCER IN A SCREENING PROGRAMME) 
MJC Biemans, PHM Peelers, ALM Verbeek, JHCL Hendriks. 
The following study was conducted among women with a false-positive test 
result to evaluate whether this result had revealed any psychological distress. 
Distress was not measured directly after referral since it is obvious that 
referral will cause anxiety. After receiving the news that no breast cancer has 
been detected, these women will be relieved: not a good time to measure 
distress either. However, after some time (in this study it was set on at least six 
months) anxiety feelings may rise again and influence the well-being of these 
women. It was assumed that after one year many other life-events would 
influence feelings of these women, so distress was measured in the period 
between 0,5 and 1 year after a false-positive test result. 
Results of this study presented in this chapter, however, are inconclusive, since 
numbers were far too small to detect reliable differences (л = 10). 
1
 Gezondheid ea Samenleving 1987; 8,189. 
Angst bij vrouwen ten gevolge van een 'foutpositieve' screeningsuitslag in een 
bevolkingsondetzoek naar borstkanker. 
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Furthermore, response was not optimal (60%) which may have caused 
selective results. 
However, the topic of the study is an important one, since screening of the 
total female population of The Netherlands will reveal approximately 2000 
women yearly with a false-positive screening test result (De kosten en effecten 
van bevolkingsonderzoek op borstkanker, interimrapport 1987). A larger 
study would be needed with higher response rates. The following study may 
serve as a first pilot study on this subject. 
Summary 
To study psychological effects of a false-positive referral, ten women with 
false-positive mammographical screening results were interviewed on average 
a year after they had been referred. The control group consisted of a group of 
never-referred women, matched on age and time of screening examination. 
The State-Trait Anxiety Inventory and Hopkins Symptoms Check List were 
administered. There was on average no difference in mean psychological 
distress in the groups. It is suggested that false-positive referral creates two 
kinds of reactions: long-term negative feelings, or positive feelings, which 
may be based on coping skills. 
Introduction 
There is increasing evidence that screening for breast cancer leads to a 
reduction in mortality from this disease (Collette et al., 1984; Shapiro et al., 
1982; Tabár et al., 1985; Verbeek et al., 1984). Trials in the UK and Canada 
are currently investigating the effect of screening in the age group under 50 as 
well as the additional effect of breast self-examination and physical 
examination at screening (Miller et al., 1985). Screening, however, has some 
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drawbacks as well, for instance psychological distress. Some women may 
sustain the adverse effect of having to undergo an unnecessary diagnostic 
evaluation and may experience considerable anxiety (Cole & Morrison, 1980). 
Only recently has this aspect become the subject of studies. In one such a study 
there was found no difference in the psychiatric morbidity six months after 
the attendance of the screened sample when compared with a matched sample 
from the community control group (Dean eia/, 1986). Another investigation 
published in 1986 suggested that emotional distress before the examination 
among women attending a breast problem clinic is negligible (Romsaas ct a/., 
1986). 
The study reported here was undertaken to examine whether psychosocial 
reactions triggered by false-positive mammographical results had any long-
term effects. It involved women from the fifth and sixth screening round of 
the Nijmegen breast cancer screening programme. 
Methods 
In this study a group of women who were referred because of suspect lesions 
showing on the screening mammogram and proved false-positive cases after 
clinical examination is compared with a group of women who were never 
referred. All study participants were scored on psychological variables 
concerning state and trait anxiety. The index group and control group were 
made up of the data base of the fifth and sixth round in 1984/85 of the 
Nijmegen breast cancer screening programme. This project was launched in 
January 1975. All Nijmegen women bom before 1940 {N= 30,000; aged 35-
64 at that time) were invited to have a mammographie screening examination 
every two years. The attendance rate was ca. 65% (Hendriks, 1982). 
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Within this programme a number of women were identified by 
mammography as suspect for malignancy, but at additional examination after 
referral no malignancy could be demonstrated. In the first five screening 
rounds in Nijmegen 801 women were referred to hospital to be clinically 
examined after single view mammography at the screening centre. Breast 
cancer was diagnosed in 302 of them. In about two-thirds of the other women 
a biopsy had been taken; the other one-third had only a clinical and physical 
examination (Peeters et a/, 1987). The classification of'falsely-referred' was 
on average 1-2 weeks since the previous mammographical screening 
examination. 
This study was restricted to women who had been confronted with a false-
positive screening referral 6-12 months before the investigation for 
psychological distress was performed. This period of time is asssumed to be 
long enough for coping with a psychological crisis (Cullberg et a/., 1983). In 
accordance with this criterion 15 false-positive cases were identified in 1984 
and 1985. True-negative or, more precisely, never-referred women were 
randomly chosen from the data base to serve as a control group. To make the 
controls more comparable to the cases they were matched on age, number of 
previous screening examinations and residential district, as a proxy variable 
for socioeconomic status. Cases (N'= 15) and controls (N= 30) had never 
been referred in a previous screening examination. All subjects were invited 
by mail to participate in this study and had an interview conducted at home. 
When necessary one reminder was sent. 
Three different instruments were used to measure psychological parameters. 
Every meeting started with a short open interview about the woman's 
experience of screening and non-screening related events. Next, the 
respondent women were asked to fill in a 40-item Dutch version of the State-
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Trait Anxiety Inventory (STAI), developed by Spielberger, Gorsuch and 
Lushene (Ploeg, 1978, Ploeg 1981) The STAI consists of two separate self-
reporting questionnaires by which two different anxietv concepts can be 
measured state- and trait-anxiety State-anxiety is conceptualized as a passing 
emotional condition of the individual charactemcd by subjective consciously 
experienced feelings of tension induced by a certain situation Trait-anxiety 
refers to relatively stable individual differences in disposition to react with 
different intensity levels of state-anxiety to psychological stress It is expected 
that people who possess a high level of trait-anxiet> will show higher levels of 
state-anxiety more frequently as compared to people with a low trait-anxiety 
score, for the first will experience more situations as dangerous or 
threatening Finally a Dutch version of the Hopkins Symptom Checklist 
(HSCL) was used (Luteijn et al, 1978) This test makes it possible to measure 
the nature and seriousness of psychoneurotic and somatic distress The 
respondents are asked emphatically to score "last week and today" In this way 
the HSCL measures the present state of well-being Seventeen items concern 
psychological symptoms, 8 items somatic symptoms, and 75 items the 
symptom dimensions of somatization, obsession compulsion, interpersonal 
sensitivity, depression and anxiety For a week one of the authors (MB) was 
trained in the use of the instrument by a psychologist 
Results 
Of all 45 women invited 27 were interviewed 10 women with a false-positive 
test result (67%) and 17 true-negative women (57%) Of the 5 non-responders 
in the false-positive group 2 did not mention a reason for not responding, 1 
was not interested and the other two gave private reasons for not responding 
Of the 13 nonresponders in the true-negative group 2 gave no reason for not 
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responding, the others mentioned illness, employment elsewhere, and removal. 
It was concluded that the non-response group was fairly random and not 
selective. Of the 27 interviewed women, 67% were aged 40-45, and 33% aged 
50-75. 
STAI and HSCL data 
The aim of the study is to compare false-positive women, some of them having 
had a biopsy, with non-referred women, in order to determine differences in 
state anxiety and items concerning well-being. To make a valid comparison 
possible it was necessary to determine whether the mean trait-anxiety in both 
groups was the same, the hypothesis being that if the mean trait-anxiety in 
both groups is the same, the state-anxiety in the false-positive group will be 
higher due to the emotional distress that the suspected existence of breast 
cancer entails. A mean score comparison of both groups is shown in Table 
4.1. 
Table 4 1 Mean test score (and standard deviation) for women with a false-positive test result 
compared with true-negative women, dichotomised to a 9 month period between referral and 
interview 
False-positive True-negaîive Standard 
Test-subject Palse-posidve True-negative s9 months >9 months Group* 
N=10 №1? N=3 N-7 N=6 N«-11 
STAI-trait anxiety 37 7 (7 6) 36 9 (9 7) 310 40 6 36 5 37 2 39 4(112) 
STAI-stateanxiety 414(164) 40 6 (132) 28 3 47 0 45 7 37 8 388(132) 
HSCL-Psy-scale 7 3 (5 1) 7 5 (4 8) 5 3 8 1 70 78 
HSCL-Somat-scale 5 6 (5 9) 4 2 (3 9) 2 3 70 4 5 4 0 
HSCL-Total-scale 32 4 (3 2) 27 9 (4 1) 15 3 39 7 31 0 26 2 
»Based on a reference group of 200 female inhabitants of the city of Leiden (The Netherlands) (Ploeg, 1981 ) 
The mean scores for trait-anxiety as well as state-anxiety were almost the 
same. All personal factors not related to mammographical experiences were 
equally distributed in both groups, except for the factors of 'work outside the 
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house' and 'perceived health at the preceding screening examination'. More 
false-positive women worked outside the house (60% vs. 24% in the control 
group) and more of them perceived their health at the previous screening 
examination as 'not too good' or even 'bad' (30% vs. 6% in the control 
group). 
It is difficult to predict the direction and magnitude of the bias in the level of 
state-anxiety, because of these baseline differences in both groups. 
The mean state-anxiety scores indicated that the false-positive women and the 
true-negative women showed almost the same anxiety levels at interview lime. 
Another hypothesis was that the shorter the time lapse since the preceding 
screening examination, the more state-anxiety would be revealed. When the 
time lapse between the screening examination and the interview was 
dichotomised into 'less than 9 months' and '9 months or more' the results as 
displayed in Table 4.1. were obtained. Table 4.1. shows for women with a 
false-positive result that the shorter the time lapse since the woman's last 
screening examination, the lower the score. With respect to the Hopkins 
Symptom Checklist similar scores of the Psych, Somat and Total scale were 
observed. Dichotomisation of the time lapse since the last screening 
examination revealed again that false-positive women with shorter follow-up 
time had lower mean scores, which finding is in contradiction with the 
hypothesis. 
Interview data 
The aim of the open interview conducted before the structured questionnaires 
were filled in was to record beforehand any negative effects or feelings due to 
the screening examination itself. The respondents' reports of their experiences 
of screening were later on analysed by a psychologist and MB, who were not 
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informed about the false-positive or true-negative status of the respondents. 
Four cases, all false-positive women, were rated as having clearly negative 
feelings concerning the previous screening examination. These four women all 
had the negative diagnosis more than 9 months ago. After these women had 
been excluded from analyses, mean scores on state anxiety of the remaining 6 
false-positive women turned out to be lower than those of the true-negative 
women: 29.3 (SD = 5.4) versus 40.6 (SD = 13.2). Similar results were 
observed in the HSCL. 
Discussion 
The total number of eligible subjects in this study turned out to be very small. 
To preclude recall bias subjects were eligible only if the time lapse between 
the final negative diagnosis (no malignancy after referral) and the interview 
did not exceed one year. At the same time, however, subjects were no longer 
eligible if the time lapse involved was much less than a year, since they were 
to be allowed enough time to cope with any psychological crises. 
Furthermore, in screening round 5 (1983/84, Л^ 28,000 invitations; 55% 
attendance rate) 106 referrals were recorded, in 57 cases breast cancer was 
diagnosed, leaving 49 false-positive cases (Peelers et ai., 1987). This suggests a 
positive predictive value of 53.8%. In other words, the absolute number of 
false-positive referrals in Nijmegen is very low at present. Although we are 
aware of the fact that it may be inappropriate to calculate mean scores for 
such small numbers, they have been presented to give an overall impression, 
for they can be compared to the mean scores of the standard groups in the 
psychological questionnaires. Still we hope that the number of women 
interviewed in the study is large enough to warrant some valid conclusions 
Distress among referred women 5-L 
about psychological aspects of false-positive referral, as they are mostly based 
on the obtained qualitative data. 
The results of the State-Trait Inventory (STAI) suggested the two groups do 
not differ in trait-anxiety or state-anxiety. The same results were obtained by 
the Hopkins Symptom Checklist (HSCL). However, the analysis of the 
qualitative data obtained from the open interviews showed that four of the ten 
false-positive women were still coping with negative experiences related to the 
false-positive test results, even though almost twelve months had passed since. 
If we excluded these four women from the false-positive group, the state-
anxiety and HSCL scores of the other 6 suggested that a false-positive test 
result may cause two extreme groups within the false-positive group as a 
whole. One group (i.e. 4 women) showed a higher level of state anxiety, 
greater somatization and more psychological problems than the true-negative 
group. The other group (i.e. 6 women) did not show any signs of having these 
problems. Their perception of health seemed to be even better than that of 
true-negative women. It also appeared that these six women had more recently 
heard they did not have breast cancer. They seemed to experience the fewest 
psychological or somatic symptoms, even fewer than true-negative women 
(see last column in table I). Women who received a negative diagnosis more 
than 9 months before the interview were worse off. A plausible explanation 
for this might be that these six women seemed to have no problems, because 
they were (still) using types of coping skills called 'defensive mechanisms' 
(Moos, 1982). These self-protective responses to stress can be based on 
denying or minimizing the seriousness of a crisis or isolating or dissociating 
their emotions. One other explanation for this might be that through the 
experience of a positive test result and subsequent testing, their ability to cope 
with stressful events later on has improved. This would be a confirmation of 
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Lazarus' coping theory (Lazarus, 1981) in which the cognitive appraisal factor 
plays a central role in the coping process. Further investigation on a larger 
sample is necessary in order to assess the exact implications of these results. 
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CHAPTER 5 
EVALUATION OF OVERDIAGNOSIS OF BREAST CANCER IN 
SCREENING WFTH MAMMOGRAPHY 
Results of the Nijmegen programme ι 
PHM Peeters, ALM Verbeek, H Straatman, 
R Holland, JHCL Hendriks, M Mravunac, 
С Rothengatter, A van Dijk-Milatz, JM Werre. 
Summary 
After 12 years of screening for breast cancer in Nijmegen (1975-1986), 
during which period six mammographie examination rounds were carried out, 
the extent of overdiagnosis was evaluated. Overdiagnosis is defined as a 
histologically established diagnosis of invasive or intraductal breast cancer that 
would never have developed into a clinically manifest tumor during the 
patient's normal life expectancy if no screening examination had been carried 
out. The whole 12-year period shows an excess of 11% of breast cancer cases 
in Nijmegen, compared with the neighbouring city of Arnhem, where no mass 
screening was performed. The incidence of breast cancers in Nijmegen in the 
IntJEpidem, in press. 
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period 1975-1978 is higher, compared with the incidence rates in Arnhem; the 
rate ratio is 1.30. For the time-intervals 1979-1982 and 1983-1986 the rate 
ratios are 1.03 and 1.01 respectively with (0.89 ; 1.18) and (0,86 ; 1.16) as 
95% confidence intervals. This leads to the conclusion that there is no 
evidence that screening programmes with modem mammography constitute a 
significant risk for overdiagnosis of breast cancers. 
Introduction 
Since the Health Insurance Plan (HIP) trial in Greater New York (Shapiro et 
al., 1982) several breast cancer screening programmes have been carried out 
all over the world. The results of the more recent ones such as the DOM-
project in Utrecht (Collette eí ai, 1984), the Nijmegen screening project 
(Verbeek eí ai., 1984), the screening programme in Florence (Palli et ai, 
1986) and the W&E trial in Sweden (Tabár eia/, 1986) show a considerable 
reduction of breast cancer mortality. But even though it is no longer disputed 
that early detection and early treatment lower the mortality of breast cancer, 
some problems remain to be solved. There is an obvious possibility that some 
cancers detected in a screening programme would never have developed into 
clinically manifest tumors during the patient's normal life expectancy. 
Screening will lead to some overdiagnosis, because it is bound to detect breast 
cancer in some women who will die from other causes before breast cancer 
would have been clinically detected in them (Morrison, 1985). Since the lead-
time in breast cancer is on average 1 year for women under age 50 and on 
average 4 years for women over 65, this category of overdiagnosis will not 
involve an important number of cases.(Shapiro et al-, 1974; Moskowitz, 1986) 
(Lead-time is the time gained as a result of the diagnosis being made earlier 
through screening). In the first screening round the number of newly detected 
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breast cancers will be relatively high because the date of diagnosis has been 
advanced. Then the situation will gradually stabilize at a slightly higher level 
because of overdiagnosis in the lead-time-period. This means that almost the 
same rate of breast cancer diagnosis is observed as before the start of the 
screening, but the diagnosis is now made earlier. However, besides the 
possible overdiagnosis of breast cancer due to lead-time, there is another 
problem, as Eddy has noted (Anonymous, 1980): 'Unfortunately there is no 
sharp boundary between nonmalignant and malignant cells, and it is quite 
possible to overdiagnose as a very early cancer a lesion that is not cancer and 
would never become cancer'. This could only be true for a small part of all 
breast carcinomas. 
The possible harmful effect of overdiagnosis is overtreatment, which leads to 
physical and mental trauma in the screened community and extra financial 
costs for the community. With reference to this problem, several terms are 
used, such as overdiagnosis, nonprogressive or noninvasive cancer, and 
pseudocancer or pseudodisease (Verbeek, 1984; Morrison, 1985; Howard, 
1987; Lundgren & Helleberg, 1982; Cole & Morrison, 1980; Boys et al., 
1982). In this study the extent of excess breast cancer is evaluated, after 6 
rounds of screening (=12 years of observation) have been carried out in the 
Nijmegen screening programme. 
Subjects and methods 
In January 1975 a population-based screening project with biennial 
mammography started in the city of Nijmegen (150,000 inhabitants). The first 
screening round (1975-76) was conducted among women bom in the period 
1910-39 (age 35-65; n= 23,000). In the subsequent screening rounds the same 
birth cohort was invited, as well as women bom before 1910 (age 65+; n = 
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7,700). To evaluate a possible excess number of breast cancers diagnosed in 
the Nijmegen programme, the incidence rate of breast cancer for women bom 
before 1939 in Nijmegen was compared with the incidence rate in Arnhem, a 
neighbouring city (л = 150,000), where no mass screening was carried out. 
Incidence rates were computed for the whole 12-year observation period 
(1975-86) and for three time intervals (i.e. 1975-78, 1979-82 and 1983-86). 
The Nijmegen rates include all cancers: screen-detected cancers, interval 
cancers as well as cancers detected among non-participants. Cases with lobular 
carcinomas in situ are not included, because they are not treated as breast 
cancer. 
Data on Arnhem patients diagnosed as having primary breast cancer have been 
carefully recorded by the Carcinoma Working Group Arnhem of five 
Arnhem hospitals. To evaluate whether Arnhem is a proper reference group 
for Nijmegen incidence rates of the two cities were compared for a 5-year 
period previous to the screening programme, 1970-1974. A second check was 
carried out by comparing mortality rates of breast cancer in both cities for the 
period 1970-79. Here one could object that by 1979 the programme had been 
in operation for 5 years, but it should be remembered that no mortality 
reduction because of screening is to be expected in the first five years of a 
programme (Shapiro eia/., 1982). Comparison of the breast cancer frequency 
was done per birth cohort. For the analyses the Cochran-Mantel-Haenszel 
method, described by Rothman and Boice (Rothman & Boice, 1979), and chi-
square tests for heterogeneity as described by Breslow were used (Breslow, 
1984). 
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Results 
Comparability 
Incidence rates of Amhem and Nijmegen for the period previous to the 
screening programme (1970-74) are shown in Table 5.1 (Hendriks, 1982). 
Table 5.1. New breast cancer cases in Nijmegen and Amhem, during the period 1970-74 
Age Person-years Observed cases Rate ratio 
35-44 
45-54 
55-64 
65+ 
АП 
Nijmegen 
40,534 
40,142 
35,566 
41,856 
158,098 
Amhem 
36,878 
41,012 
36,862 
42,387 
157,139 
Nijmegen 
32 
59 
43 
99 
233 
Amhem 
24 
65 
63 
92 
244 
1.21 
0.93 
0.71 
1.09 
0.95* 
* Crude rate ratio is 0.95. The age-adjusted rate ratio, according to Mantel-Haenszel is 0.96; 
95% confidence interval (0.81 ; 1.11). 
Chi-square for heterogeneity is 3.96, df = 3 ; ρ = 0.27 
The results show a somewhat lower, although statistically not significant, 
incidence rate for breast cancer in Nijmegen. The age-adjusted rate ratio is 
0.96 (95% confidence interval 0.81; 1.11). 
Table 5.2 compares the breast cancer mortality rates in the two cities for the 
period 1970-79 (Hendriks, 1982). 
Again a lower mortality rate in Nijmegen is observed: the age-adjusted rate 
ratio is 0.91, but it is not statistically significant (95% confidence interval 
0.77; 1.05). Chi-square tests for heterogeneity in both comparisons were not 
significant, indicating no differences between the rate ratios in the different 
age groups. From these comparisons it may be concluded that Amhem is a 
proper reference group for Nijmegen with regard to base-line risk of breast 
cancer in the female population. 
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Table 5.2. Deaths from breast cancer in Nijmegen and Amhem, during the period 1970-79 
Age Person-years Observed deaths Rate ratio 
35-44 
45-54 
55-64 
65+ 
All 
Nijmegen 
80,061 
79,716 
71,488 
88,737 
222,595 
Amhem 
70,433 
79,537 
73,582 
89,752 
203,200 
Nijmegen 
14 
44 
49 
141 
248 
Amhem 
18 
67 
49 
140 
274 
0.68 
0.67 
1.03 
1.02 
0.83* 
* Crude rate ratio is 0.83. The age adjusted rate ratio, according to Mantel-Haenszel is 0.91; 
95% confidence interval (0.77;1.05). 
Chi-square for heterogeneity is 4.80, df = 3 ; ρ = 0.13 
Incidence rates Í975-1986 
During the period 1975-1986 six screening rounds were carried out. All 
breast cancer cases diagnosed in Nijmegen and Amhem, are listed in Table 
5.3, for 4 birth cohorts. For the whole period 1975-86 there is an overall 
excess of 11% of breast cancer cases in Nijmegen, compared with Amhem. 
However, the effect in the four birth cohorts is significantly different, (X2= 
13.56, df = 3, ρ = 0.004), so the summary-rate ratio of 1.11 does not 
adequately represent the data. There is a tower incidence rate for women of 
birth cohort s 1909 in comparison with Amhem, and there is an excess rate 
for women of birth cohort a 1910, in particular for those bom in 1920-1929. 
Table 5.3. New breast cancer cases in Nijmegen and Amhem for the period 1975-86 
Birth-
cohort 
1930-39 
1920-29 
1910-19 
s 1909 
AU 
Person-
Nijmegen 
91,208 
92,211 
78,910 
71,724 
334,053 
•years 
Amhem 
81,309 
92,727 
79,538 
73,718 
327,292 
Observed 
Nijmegen 
139 
244 
219 
213 
815 
cases 
Amhem 
115 
174 
186 
253 
728 
Rate rati 
1.08 
1.41 
1.19 
0.87 
1.10* 
* Crude rate ratio is 1.10. The birth-year-adjusted rate ratio, according to Mantel-Haenszel is 
1.11; 95% confidence interval (1.02 ; 1.20). Chi-square for heterogeneity is 13.56, df - 3 ; 
ρ =0.004 
Evaluation of overdiagnosis 65 
The birth year rate ratios for the 3 time intervals (1975-78; 1979-82; 1983-
86) are: 1.30; 1.03 and 1.01 respectively (see Table 5.4). There is a clear 
decline in rate ratio, approximating unity in the last 4-year period. Only in the 
first period (1975-78) does the rate ratio differ significantly from unity. 
Table 5.4. New breast cancer cases in Nijmegen and Arnhem for the periods 1975-1978, 
1979-1982 and 1983-1986 
Period Birth-
cohort 
1975-78 1930-39 
1920-29 
1910-19 
£1909* 
Crude rate ratio is 1.27. 
Pereon-yeais 
Nijmegen Amhcm 
31,096 27,363 
31.631 31,820 
27,795 28,084 
30,315 30,689 
Birth-year-adjusted rate ratio is 1.30; 95% CI ( 1.14 ; 
Chi-square for heterogeneity is 8.04, df = 3; p= 0.05 
1979-82 1930-39 
1920-29 
1910-19 
s 1909 
Crude rate ratio is 1.04. 
30,352 27,214 
30,837 31,072 
26,595 26,672 
23,702 24,446 
Birth-year-adjusted rate ratio is 1.03; 95% CI (0.89 ; 
Chi-square for heterogeneity is 5.20, df = 3; ρ = 0.16 
1.46) 
1.18) 
1 
Obeserved ι 
Nijmegen 
30(3)** 
95(6) 
75(10) 
106(3) 
59(5) 
70(3) 
71(2) 
69(-) 
cases 
Anihem 
22 
53 
52 
108 
45 
59 
61 
93 
Rale 
Ratio 
1.20 
1.80 
1.46 
0.99 
1.18 
1.20 
1.17 
0.77 
26,732 
29,835 
24,782 
18,583 
50(7) 
79(11) 
73(10) 
38(3) 
48 
62 
73 
52 
0.94 
1.28 
1.01 
0.77 
1983-86 1930-39 29,760 
1920-29 29,743 
1910-19 24,520 
S1909 17,707 
Crude rate ratio is 1.00. 
Birth-year-adjusted rate ratio is 1.01; 95% CI (0.86 ; 1.16) 
Chi-square for heterogeneity is 5.20, df = 3; ρ - 0,16 
CI = confidence interval 
* This cohort was invited for their first screening examination in 1977-1978 (second 
screening round) 
** In parentheses numbers of intraductal cancer, included in the total number of observed 
cancers in Nijmegen. 
Discussion 
Overdiagnosis is often mentioned as a serious side effect of screening for 
breast cancer (Beahrs & Smart, 1979; Skrabanek, 1985), Radiologists, 
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pathologists and surgeons feel accused of diagnosing and treating breast cancer 
in women who are actually healthy. Overdiagnosis and overtreatmcnt may 
occur in everyday clinical practice as well, where people are treated because 
of disease even though they would never get seriously ill or die from the 
disease. In a clinical setting, however, people seek help on their own initiative 
because of complaints. 
In mass screening, which is offered as a public health service to apparently 
healthy women, overdiagnosis is more serious and should be considered 
accordingly. Screening detects disease in an earlier stage and the histologic 
distinction between benign and malignant lesions poses a much greater 
problem compared with lesions of symptomatic patients. Screening leads to 
earlier diagnosis of disease, so a screened population will have a higher 
cumulative rate of diagnosis than an un-screened population that is similar in 
other aspects. The cumulative number of cancers in a screened population will 
therefore always be higher when compared with an unscreened population. Up 
to the last screening round new cancers will be detected which otherwise 
would have surfaced later. The HIP-study and the Swedish W&E trial as well 
as the Nijmegen programme (Verbeek, 1985) indeed show an excess number 
of cumulative breast cancers during the screening programme. After 7 years 
of observation in the Swedish W&E trial (Tabár, 1985) a 30% excess of 
invasive cancers was diagnosed in the study group, compared with the control 
group. To evaluate possible overdiagnosis it is not correct to look at 
cumulative numbers since they will be higher because the date of diagnosis has 
been moved back in time, resulting in a relatively high number of cancers 
during the beginning years of the programme. However, after a screening 
programme has been terminated, the number of cancers is expected to 
approach the number of cancers found in the absence of screening by the time 
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the screen-detected case with the longest lead-time would have been diagnosed 
as a result of symptoms (Morrison, 1985). In the HIP study the cumulative 
number of diagnosed cases in the screened group clearly exceeded the number 
in the control group through the fifth year, but thereafter the cumulative 
number of cancers in both groups became equal (Shapiro et al., 1974; Shapiro 
et ai, 1985) indicating that in this programme little pseudodisease was 
detected. 
Since the HIP-study, however, mammographie technique and its capacity to 
detect minimal cancers have improved. It is therefore not unlikely that as a 
result more pseudodisease will be detected. An evaluation of overdiagnosis in 
another Swedish project (Lundgren & Helleberg, 1982) which started in 1974, 
showed a 50% excess of breast cancer during 6.25 years of observation, in 
which 3 screening rounds were performed. In the analysis, breast cancers 
detected during the first screening round were regarded as prevalent cancers 
and left out in the comparison of incidence rates. The result was no excess 
diagnosis of cancers when compared with national incidence rates. 
In the present study incidence rates of Nijmegen and Arnhem were compared 
for three time intervals. For the last two periods the incidence rate ratios were 
approximately one, indicating no substantial degree of overdiagnosis. 
Because of the non-randomised design of the Nijmegen programme a proper 
control group is lacking. The women of the city of Arnhem, about 15 miles 
from Nijmegen, seem a good reference group, because the overall incidence 
rate for 1970-74 and mortality rate for 1970-79 did not differ significantly 
from the Nijmegen rates. Since the beginning of 1975 there has been careful 
registration of breast cancer diagnosis in both cities. There is close 
cooperation between the 2 hospitals in Nijmegen and the 5 hospitals in the 
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Arnhem region. It seems unlikely that under- or overreporting is responsible 
for the observed decline in the incidence rate ratio. 
The attendance rate in the Nijmegen programme was 85% for the first 
screening round (1975-1976). For the second screening round (1977-1978) 
elderly women were invited too. Because of their lower attendance rate, the 
overall attendance rate dropped to 65% in the second screening round. Since 
then there has been only a small decline in cohort-specific attendance rates up 
to the last screening round (5-10%). These small declines in cohort specific 
attendance rates are not assumed to be responsible for the observed decline in 
the incidence rate ratios. 
In the course of the 12-year observation period, the cohort of scrcenees has 
aged. If overdiagnosis were present in younger women only, one could argue 
that ageing is the reason for the decline in the incidence rate ratio. However, 
in the 1983-1986 interval the total cohort was on average only 8 years older 
compared with the 1975-1978 interval. 
Unfortunately no comparison of the disease stage distributions among the cases 
of the two cities was possible. A valid comparison is impossible because 
different physicians may classify differently, different examinations may be 
performed to investigate the extent of the disease and registration and 
documentation of disease stage may be different as well. 
In Nijmegen, 7.8% (63) of all 815 carcinomas, diagnosed between 1975-86, 
were intraductal cancers (ductal carcinoma in situ, DCIS). The period 1983-86 
yields a percentage of 12.9 (31/240) of DCIS, while this percentage is 19.4 
(21/108) among screendetected carcinomas only. In a clinical setting this rate 
is only 3-5%.(Rosen et al., 1980; Rosner étal., 1980). Some surveys (Rosen et 
al, 1980; Rosner et al, 1980; Betsill et al. Page et al, 1982) suggest that not 
all in situ carcinomas will grow into an invasive state. If some of the 
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intraductal cancers, detected during the screening programme in fact had not 
grown into an invasive state, this would mean overdiagnosis. It was not 
possible to trace such a small degree of overdiagnosis in this study, because of 
statistical variance. 
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CHAPTER 6 
THE OCCURRENCE OF INTERVAL CANCERS IN THE NIJMEGEN 
SCREENING PROGRAMME1 
PHM Peeters, ALM Verbeek, JHCL Hendriks, 
R Holland, M Mravunac, GP Vooijs. 
Summary 
Since January 1975 a population-based screening programme for the early 
detection of breast cancer has been carried out in the city of Nijmegen. During 
5 interscreening periods of 2 years each a total of 158 so-called interval 
cancers were diagnosed. Careful revision of all screening and diagnostic 
mammograms was executed. Of all interval cancers 26% were missed' at the 
previous screening examination (due to technical or observer error), 16% 
were radiographically occult at the time of diagnosis and 58% were 'true' 
interval cancers. Interval cancers were regarded as 'true' when an obvious 
lesion was observed on the diagnostic mammogram while no suspect signs 
were seen on the previous screening mammogram. 
1
 Br J Cancer, in press 
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The prevalence of 'missed' cancers did not decline in the course of the 
screening programme. Radiographically occult tumours were localised mostly 
in Wolfe's P2/DY breast parenchyma (83%), 33% were lobular invasive, and 
25% ductal non-invasive. True' interval cancer cases (58%) showed the same 
overall survival as control breast cancer patients, diagnosed in a non-
screening situation. 
Shortening the screening interval would reduce interval cancer rates and 
probably further decrease breast cancer mortality in a screened population. 
However, from the present series of interval cancers 63% would not have 
been prevented by an annual screening examination. As regards women under 
age 50 annual screening would still leave 66% of all interval cancers in this 
age group undetected. Probably more benefit will be gained by searching for 
new imaging techniques to reduce numbers of 'missed' cancers and to detect 
lobular invasive and ductal non-invasive cancers in dense breast parenchyma. 
Introduction 
Within any screening programme for the early detection of breast cancer, 
women are diagnosed as having so-called interval cancer. These cancers 
surface among negative screenees before the next scheduled examination 
would have taken place. Of all breast cancers in a screened population about 
20-35% are diagnosed within 2 years after the last screening examination 
(Verbeek, 1985; Tabár étal., 1987; Moskowitz, 1986; de Waard et al., 1984; 
Lundgren, 1979). The survival of patients with interval cancers turned out to 
be just as bad as the survival of patients diagnosed outside screening 
programmes (Holmberg et al, 1986; Shapiro etaL, 1982). This finding would 
seem to suggest, that shortening the screening interval to, say, one year might 
further decrease breast cancer mortality in a population offered a screening 
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programme. The aim of the present study was to search for more evidence 
validating such recommendations. The issue of screening frequency is 
especially relevant for women under age 50, since on the one hand no clear-
cut evidence of breast cancer mortality reduction has been demonstrated so far 
in this age group, and on the other hand relatively high interval cancer rates 
have been observed (Tabár et al., 1987; Moskowitz, 1987). 
Subjects and methods 
All data came from the Nijmegen (150,000 inhabitants) screening programme. 
This population-based project started in January 1975. Single-view 
mammography was carried out as the only screening examination every two 
years. In the first screening round (1975/1976) women born in the period 
1910-1939 (л = 23,000) were invited. In the subsequent screening rounds 
women bom before 1910 (n= 7,700) were invited too; in the fifth screening 
round the cohort of women bom in the period 1940-1944 (n= 3,900) was 
invited as well. The attendance rate was highest for women under 50 in the 
first screening round (87%) and lowest for women aged 65 or over in the 
sixth screening round (31%). Up to December 1986, 6 screening rounds were 
performed. In the 5 interscreening periods 158 breast cancer cases were 
diagnosed. Two synchronic interval cancers were found. Because some women 
did not return for screening at the scheduled two-year interval, some breast 
cancers were diagnosed in these non-attenders at intervals greater than two 
years after screening. These so-called 'pseudo-interval' cancers were not 
included in this analysis. 
All screening and diagnostic mammograms of the interval cancer cases were 
carefully reviewed by the radiologist and classified into one of the following 3 
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groups. (In 5 cases the screening or diagnostic mammogram was not available. 
They were all diagnosed in the early years of the screening project.) 
'Missed' cancers. Forty out of all interval cancers were classified as missed 
cancers, as due to either technical or observer error. 
Radiographically occult cancers. Twenty-four of all interval cancers were 
radiologically occult at the time of diagnosis. 
True' interval cancers. Eighty-nine cancers showed a clear lesion on the 
diagnostic mammogram and no suspect signs at the preceding screening 
examination. 
It was evaluated whether the number of 'missed* cancers decreased during the 
12-year observation period. Interval cancers were compared with breast 
cancers, detected at one of the 5 screening rounds, in terms of such 
radiological and prognostic aspects as Wolfe classification, mammographical 
tumour size, age at the previous examination, Quételet index, oestrogen 
receptor positivity, and axillary lymph node involvement. To evaluate the 
prognosis of the 'true' interval cancers the overall survival of these 89 patients 
was compared with control breast cancer patients in the non-screened 
population. These control patients were recruited among women who were 
diagnosed for breast cancer before they received an invitation for a first 
screening examination. 
Distributions of variables in 2 groups were compared with standard chi-square 
tests. Survival curves were computed with the actuarial or lifetable method, 
and the standard errors of these curves computed according to the Greenwood 
formula. To test equality of survival curves for 2 groups, the log-rank test 
was used (Mantel, 1966). Adjustment for age on survival was studied with the 
proportional hazards model (Cox, 1972). 
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Results 
Interval cancers 
Interval cancers occurred more frequently in younger women. In addition to 
54 cancers detected by screening in women younger than 50 years, 51 were 
diagnosed between two consecutive screening examinations. For women aged 
50 years or older the figures were 251 and 107 respectively. 
Crude interval cancer rates remained relatively stable over the 12-year period, 
from 1.57 interval cancers per 1000 screened women in 2 years follow-up 
after the first screening round to 1.61 per 1000 after the fifth screening 
round. Even when only regular participants (=women attending a screening 
examination every two years) were included interval cancer rates remained 
roughly stable: 1.63 per 1000 screenees after the first examination, 1.80 per 
1000 after second, 1.97 per 1000 after third, 2.21 per 1000 after fourth and 
1.27 per 1000 after the fifth examination. The seven-years overall survival for 
the total group of interval cancers was 74.6% (SE= 4.3%). 
Table 6.1 and 6.2 show distributions of interval cancers according to age, 
screening round and time interval since the preceding negative screening. 
Table 6.1. Number of screened women, number of screen-detected and interval cancer tases 
(all screenees). 
Age at 
screening 
<50 
50-64 
65+ 
Round I 
(75 76) 
#Scr Scrini 
9,681 20 15 
9,578 53 15 
443 2 1 
Round 2 
(77-78) 
#Scr Scr Int 
7,165 12 9 
8,301 32 18 
4,321 35 9 
Round 3 
(79 80) 
#Scr Scrlnt 
5,508 8 10 
7,459 21 17 
3,662 20 3 
Round 4 
(81-82) 
#Scr Scrlnt 
4,276 6 12 
7,275 16 17 
3,540 23 6 
Round 5 
(83 84) 
#Scr Scrlnt 
5,911 8 5 
7,032 26 11 
3,227 23 10 
Total 
Scr Int %Ы 
54 51 48 6% 
148 78 34 5% 
103 29 22 0% 
305 158 34 1% 
#Scr= Number of screened women 
Sa= Screen-detected cancer 
lnt= Interval cancer 
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Table 6.2. Distribution of interval cancers according to age, screening round and time interval 
ader the negative screen. 
Age at Round 1 Round 2 Round 3 Round 4 Round 5 
screening (75-76) (77-78) (79-80) (81-82) (83-84) 
Int' Int* Int' Int* Int' InP Int' Int^ Int' Int^ 
<50 4 1 1 4 5 6 4 5 7 4 1 
50-64 4 1 1 8 10 9 8 3 14 5 6 
65+ 1 0 4 5 2 1 1 5 7 3 
Inl'= 0-12 months after a negative screen. 
Int2» 13-24 months after a negative screen. 
'MissecT cancers 
Of all 153 interval cancers 40 (26%) were classified as 'missed' cancers. 
There were various reasons why these cancers were not diagnosed at screening 
examination. 
In 14 cases the site of the tumour was outside the image field (technical error) 
(Table 6.3): twice because of incorrect positioning and 12 times because of an 
exceptional location of the tumour (high on the chest wall or in the tail of the 
breast). In 26 cases at revision suspect lesions could be identified in the 
previous screening mammogram (observer error): in 10 of these those 
changes were not sufficiently characteristic to warrant a diagnosis of 
malignancy. 
Of all interval cancers diagnosed in the first interval, e.g. between first and 
second screening round, 16.1% were classified as missed (5/31). For the 
second, third, fourth and fifth interscreening period these figures were 21.9% 
(7/32); 44.8% (13/29); 20% (7/35); 30.8% (8/26) respectively. Despite great 
variation because of small numbers, these figures demonstrate no decline in 
the number of 'missed' cancers since the start of the screening programme. 
Patients with 'missed' interval cancers did not differ from screen-detected 
cases in terms of age at the previous screening examination, Quételet index, 
The occurrence of interval cancers 79 
Table 6.3. Reasons for missed detection on screening mammogram. 
Screening error 
-Technical error 
-Observer error 
-Incorrect positioning 
-Strange location tumour 
-Direct signs (*) 
-Less specific signs (**) 
2 
12 
16 
10 
•Direct signs: presence of a mass, malign microcalcificalions, nipple 
retraction diffuse lymphedema, skin thickening orspiculation. 
**Less specific signs: a vague progressive density in a specific area or slight 
disturbance of the architectural pattern, or slight 
asymmetry of breast tissue. 
oestrogen receptor positivity or histologic tumour type. They did differ in 
type of breast parenchyma, although differences in percentages were not 
statistically significant. (50% P2/DY vs 38%, ρ = 0.15) 
Also lymph node involvement was more frequently (32% vs 22%, p= 0.20) 
and tumour size was significantly larger (95% s 10mm vs 73%, ρ = 0.0007). 
This may be due to the fact that diagnosis was made on average 11.3 months 
later. 23 of the 40 'missed' interval cancers were diagnosed within one year. 
RadiographicaUy occult cancers. 
Of the total group of interval cancers 24 (15.7%) were classified as 
radiologically occult. In 16 of these women no signs at all were found on the 
diagnostic mammogram, white in the other eight mammograms, on careful 
inspection, very subtle signs, such as a vague density or a slight disturbance of 
the breast architectural pattern could be identified. Diagnosis was made on 
average 13.3 months after the preceding screening examination. 10 of the 24 
occult interval cancers occurred within one year after the previous screening 
examination. 
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Table 6.4 Percentages of epidemiological, histological and radiological aspects of interval 
cancers (i.e. 'missed' cancers, radiographically occult cancers and 'true' interval cancers), 
screendetected cancers and cancers of control patients (i.e with a diagnosis of breast cancer 
before any screening invitation 
Factor 
Age •·. 50 years1 
Quetelet index <252 
Oestrogen receptor pos3 
Wolfe P2/DY 
Axillary node involvement4 
Tumour size < 10 mm5 
Histology DCIS* 
Duct invasive 
Lobular invasive 
Else'' 
'Missed· 
cancers 
( n - 4 0 ) 
27 5 
37 5 
75 7 
5 0 0 
32 4 
5 0 
. 
74 4 
128 
12 8 
Radiographically 
occult cancers 
( n - 2 4 ) 
50 0 
62 5 
6 4 3 
83 3 
28 6 
_ 
25 0 
4 1 7 
33 3 
-
Trae' inter 
val cancers 
(n = 89) 
30 0 
32 6 
65 8 
47 2 
35 5 
5 6 
5 6 
66 3 
16 9 
11 2 
Screendetected 
cancers 
(n = 305) 
17 7 
37 4 
80 0 
38 0 
22 4 
27 2 
9 9 
75 0 
6 9 
8 2 
Control 
patients 
(n-M27) 
38 6 8 
9 
62 5 
50 4 
58 0 
10 4 
3 2 
81 1 
9 5 
6 3 
') Age at screening examination 
J) Quetelet Index = kg/m2 
3) Oestrogen receptor positive г 10 fmol/mg 
^ In the early years of the screening programme it was neither a national nor a local practice to 
remove the axillary lymph nodes for histologic examination 
5) Size of the tumour on the mammogram at diagnosis 
6) DCIS = Duct Carcinoma in Situ 
^ Else - tubular carcinoma, medullary carcinoma, papillaiy carcinoma 
*) Age = age at diagnosis 
') Not known for control patients 
Because radiographically occult breast cancers mark the border of the 
sensitivity of the mammographical test they were compared with screen-
detected cancers and 'true' interval cancers for specific characteristics (table 
6.4). Women with an occult interval cancer proved to be younger when 
compared with patients with screen-detected cancers (50% < 50 years vs 18%, 
ρ = 0 0001) and with patients with 'true' interval cancers (50% vs 30%, ρ = 
0.07). They also had a lower Quetelet index (63%<25 vs 37% among screen-
detected patients ρ = 0.02; vs 33% among patients with 'true' interval cancer ρ 
= 0.008) which is probably associated with the younger age. There was a 
striking difference in Wolfe classification and histologic type. Of occult 
tumours 83% were localised in P2/DY breast parenchyma, compared to 38% 
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(p = 0.00001) among screen-detected and 47% (p = 0.002) among 'true' 
interval cancers. 25% of occult cancers were ductal non-invasive, and 33% 
were invasive lobular: both these rates were higher than those of screen-
detected and 'true' interval cancers. (10% and 7% among screen-detected, and 
6% and 17% among 'true' interval cancers respectively). 
True' interval cancers 
On revision of all interval cancers 89 (58.2%) were not detectable on the 
screening mammogram. In these patients seven-year overall actuarial survival 
was 72.0% (SE = 6.1%). In control patients, diagnosed for breast cancer 
before being eligible for a screening invitation, overall survival was 60.2% 
(SE = 5.2%). Differences in survival curves approached statistical significance 
(Log-rank chi-square = 3.2, ρ = 0.07). Control patients, however, were older 
when compared with 'true' interval cancer patients (47% aged 65 years or 
older vs 21%). Age (continuous) included as an explanatory variable in a 
proportional hazards model showed a hazard of 0.97 (p= 0.91) for interval 
cancer patients compared with control patients. This indicated the hazard to be 
the same for individuals with 'true' interval cancers as for control patients. 
The same results were found in proportional hazards models for women 
below age 50, and for women aged 50 or older. 
Epidemiological, histologic and radiographic features are displayed in table 
6.4. True' interval cancers did not differ from breast cancers in the control 
group, they only showed less axillary involvement (35.5% vs 58.0% ρ = 
0.005). Compared with screen-detected cancers 'true' interval cancers were 
larger (94% ^ 10mm vs 73% p= 0.02). Diagnosis was made on average 15.2 
months after the previous screening examination. 36% of 'true' interval 
cancers were diagnosed within one year after the screening examination. 
82 The occurrence of interval cancers 
Discussion 
The results of breast cancer screening projects such as the HIP-trial in the 
United States (Shapiro et al, 1982) the DOM-project in Utrecht (Collette et 
al., 1984) the Nijmegen screening project (Verbeek et al., 1984), the Italian 
project (Palli et al., 1986) and the Swedish trial (Tabár et al., 1985a) show a 
considerable reduction of breast cancer mortality. But even though early 
detection and early treatment are no longer disputed as being beneficial, some 
unsolved problems remain. One of the major problems one faces in a breast 
cancer screening project is the number of interval cancers. In the Nijmegen 
programme, where a screening examination was performed every 2 years, 
crude interval cancer rates remained relatively stable over the 12-year period. 
Other studies showed similar interval cancer rates. (Baker, 1982; Frisell et al., 
1987; Tábar étal., 1985b). Interval cancers occurred more frequently among 
women under 50 years of age, when compared to women aged 50 or older. 
For younger women the ratio between interval cancers and screen-detected 
cancers was about 1:1 while this was about 1:2.5 for women aged 50 or older. 
Previous studies (Holland eia/., 1982; Newsome, McLelland, 1986; Martin et 
al., 1979; van Rosen et al., 1985) showed one third of all interval cancers to 
be missed at a preceding screening examination due to either technical or 
observer error. In the present study 26% of interval cancers were missed. 
This percentage did not decline in the course of the programme. To some 
extent this may have been caused by the entry of new cohorts of women into 
the screening project. In the Nijmegen programme women bom in the period 
1940-44 were not invited for a screening examination until 1983-84. Reading 
mammograms of these young women is difficult due to high density of the 
breast parenchyma. Some of the missed cancers, however, were due to non-, 
specific changes, such as a vague progressive density or a slightly disturbed 
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architectural pattern. Referral of such lesions for further clinical evaluation 
probably would have resulted in a large number of false-positive screening 
results. 
From a total of 153 interval cancers 16% were radiographically occult at the 
time of diagnosis. Occult cancers are clinically detectable before they show 
mammographically suspect signs. During growth they tend to remain obscured 
by dense P2/DY breast parenchyma. Occult cancers often were of lobular 
invasive or ductal non-invasive histological type. In other studies about 5-7% 
of breast cancer patients were reported to have negative mammograms. 
Patients were younger compared with all other breast cancer patients. (Bums 
et al, 1979; Cahill et зЛ, 1981) Here the limits of modem mammography 
have been reached since in dense breast parenchyma these types of breast 
cancers probably can not be visualised (Holland et ai., 1983). 
Of all interval cancers 58% showed no suspect lesions on a previous screening 
mammogram, while they were visible at the time of diagnosis. They were 
either masked in some way at the previous examination or were newly grown 
which implies a high growth rate. A similar percentage of 'true' interval 
cancers (52%) was found in the Stockholm screening programme (Frisell et 
al., 1987). Although in patients with 'true' interval cancers axillary lymph 
node involvement was statistically significantly less frequent (36% vs 58%) 
when compared with control breast cancer patients, seven-year overall 
survival was equal. These results are identical to those reported by others 
(Holmberg et al, 1986; Shapiro eia/, 1982). 
It is often argued that shortening the screening interval would reduce the 
number of interval cancers (Tabár et al., 1987; Moskowitz & Gartside, 1982). 
Especially the high proportion of interval cancers occurring in women under 
age 50 is reported to cause the absence of a clear reduction in mortality in 
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women from this age-group, after participating in a screening programme. 
More frequent screening will probably not affect the number of 'missed' 
cancers, since the same error rates of about 30% are found in studies with 
different screening intervals. (Baker, 1982; Holland et al., 1982; Newsome & 
McLelland, 1986; Martin eia/, 1979). In the Nijmegen project the prevalence 
of 'missed' interval cancers did not decrease during the progress of the 
programme. More frequent screening will certainly not improve the detection 
of radiographically occult breast cancers, it can only influence the 'true' 
interval cancer group of 58%. However, since 32 of these 89 interval cancers 
occurred within one year after the previous screening examination, an annual 
screening examination would still leave 40 ('missed' cancers) plus 24 
(radiographically occult cancers) plus 32 ('true' interval cancers occurring 
within one year) undetected. So from the present series of 153 interval cancers 
96 (63%) would not have been prevented by more frequent screening. As 
regards women under age 50, from a the total of 51 interval cancers (50 ; 1 
missing) 11 were 'missed' at the previous screening examination, 12 were 
radiographically occult and 10 of the 'true' interval cancers occurred within 
one year after the preceding screening examination. For this age-group 
shortening the screening interval from 2 to 1 year would prevent 34% of 
interval cancers. This age-group would probably benefit more from the 
development of new imaging techniques to detect specific lobular invasive and 
ductal non-invasive cancers in dense breast tissue. 
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CHAPTER 7 
BREAST CANCER SCREENING: A CRITICAL APPRAISAL' 
PHM Peeters, ALM Verbeek, GA Zielhuis, GP Vooijs, 
JHCL Hendriks, R Holland, M Mravunac. 
Summary 
Breast cancer screening with mammography is strongly advocated by some 
and rejected by others. Discussions in medical literature focus on the 
beneficial and unfavourable effects of breast cancer screening. Among the 
latter are the suggested excess mortality rate of screen-detected breast cancer 
patients, the high number of unnecessary biopsies, the possibility of 
overdiagnosis and subsequent unnecessary treatment, and the occurrence of 
interval breast cancer cases. It is concluded that screening can to a certain 
extent prevent women from dying of breast cancer but some negative effects 
are unavoidable. However, adequate training of the screening-team can 
minimize the number of unnecessary biopsies and the occurrence of interval 
cancers. Research is needed to evaluate the natural course of so-called 
1
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'minimal' lesions, and to optimalize screening tests. The search for new 
(imaging) techniques is needed to detect lobular cancers in dense breasts. 
Introduction 
An estimated one out of every 10 women in Western countries will ultimately 
have breast cancer (Boice, 1986). With the current survival rates at least 35 
per cent of women with invasive tumours will die of the disease (Silverberg & 
Lubera, 1986; Host & Lund, 1986). For decades breast cancer has been the 
leading cause of cancer death in Western women: about 20 per cent of all 
cancer deaths were due to breast cancer (Silverberg & Lubera, 1987). 
At present no methods are available to reduce the incidence of breast cancer. 
On the other hand it has been shown beyond reasonable doubt that early 
detection of breast cancer can result in reduced breast cancer mortality. 
Numerous screening projects for breast cancer have been carried out and 
many will be started in the future. Both in scientific and public forums 
positive as well as negative effects of screening with mammography are 
extensively discussed. The amount of evidence on both aspects is 
comprehensive. In this overview the main issues related to breast cancer 
screening will be outlined. 
Beneficial effects of screening 
It is widely accepted that screening with mammography reduces breast cancer 
mortality (Day & Miller, 1988; Day ef ah 1986; Feig, 1988). The most 
convincing evidence came from two randomised population-based trials: both 
the HIP-study in Greater New York (started in 1963) and the Swedish W&E 
trial (started in 1977) showed a 40 per cent reduction in breast cancer 
mortality in women aged 50 years and over invited to screening (Shapiro et 
A critical appraisal 91_ 
al., 1982; Tabár eí al., 1985). Recently, results from the UK-trial (non-
randomised) have become available, that showed a 20% mortality reduction in 
the screened population (UK trial of early detection of breast cancer group, 
1988). Although this result fell just short of statistical significance, it was 
consistent with the hypothesis that screening can achieve a worthwile mortality 
reduction. Soon after the UK-trial, a first "negative" randomised trial was 
published: the Malmö mammographie screening trial showed no breast cancer 
mortality reduction in the study population after 8.8 years of follow-up. This 
result probably was influenced by the fact that some women in the control 
group had mammography. The authors estimated a 24 percentage of women 
who had undergone mammography in the control group. Although this so-
called 'infection' might have masked a real effect, the most important reason 
of the negative result of the Malmö study most probably was a shortage of 
statistical power. Although the power was estimated to be 90% at the start of 
the trial, it was only 50% at the moment of presenting the results. Failure to 
detect an effect in such a low power study is to be expected. Moreover breast 
cancer mortality figures for women over 55 indeed showed favourable effects. 
The result was a 20% mortality reduction in this age group comparable with 
the results of all other programmes. Case-control studies from the non-
randomised projects in Nijmegen (Verbeek et ai, 1984), Utrecht (Collette et 
al, 1984) (Holland) and Florence (Italy) (Palli eia/., 1986) reported similar 
results of a 30-50% breast cancer mortality reduction in women 50 years and 
over at the initial screening examination. Although case-control designs may 
be subject to various kinds of bias, the identical results derived from 
randomised trials strongly suggest a real positive effect of screening. 
In women under 50 years of age no beneficial effects so far have been 
reported. This could be due to a lack of adequate numbers of screened women 
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and/or inadequate follow-up time in the reported studies (Andersson et al., 
1988; Shapiro et al., 1982; Tabár et al, 1985; Palli et al., 1986; Verbeek et 
aA, 1985; Eddy et a/, 1988; Bailar, 1988; Shapiro et al., 1988), since overall 
survival rates in younger breast cancer patients are more favourable (Adami 
et al., 1986). On the other hand, it may well be that more frequent (Tabár et 
al., 1987) and/or more aggressive (Moskowitz & Gartside, 1982) screening is 
required to achieve any effect in this age-group. 
Up to now no effect of breast cancer screening has been shown in population 
mortality statistics, neither on breast cancer mortality, nor on overall 
mortality (Bailar & Smith, 1986). Skrabanek therefore questioned the 
effectiveness of screening on breast cancer (Skrabanek, 1988a). However, to 
reduce breast cancer mortality on a population level, for example in the U.S., 
screening has to be widely accepted. If screening actually reduces breast 
cancer mortality by 50%, an attendance rate of 10% in the whole of the U.S. 
will ultimately reduce breast cancer mortality by only 5% in the total 
population. Furthermore, as was shown for cervical cancer screening projects, 
centrally organised population-based programmes were more effective than 
uncoordinated screening (IARC Working group on evaluation of cervical 
screening programmes, 1986). 
Although a breast cancer mortality reduction of 30-50% is quite impressive, 
overall mortality from all causes will hardly change, since breast cancer 
deaths constitute only about 5-10% of overall mortality (Skrabanek, 1985a, 
1988a, 1988b; Wright, 1986). In fact, overall mortality in the study 
population did not decrease in the Swedish W&E trial after 7 years of follow-
up (Wright, 1986, 1987; Shapiro, 1987) and only slightly in the HIP-trial after 
10 years of follow-up (Shapiro et al., 1988). This was probably due to 
statistical variance, since very large trials would be needed to demonstrate 
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such small changes in overall mortality. Rates of mortality from all causes of 
death ultimately have to become equal in the two groups (since everyone has 
to die), regardless of the effect on breast cancer mortality. Therefore life 
expectancy seems to be a more appropriate measure for analysing a 
programme's impact (Miettinen, 1985). 
It is also possible that reduction in the number of breast cancer deaths is 
accompanied by a rise in mortality from other causes without net benefit 
(Skrabanek, 1985b), because breast cancer has been associated with the 
development of other cancers, such as cancer of the endometrium, ovaría and 
colon (Kelsey, 1979). A follow-up of breast cancer patients in both the study 
and control group of the Swedish W&E trial indeed showed a greater 
mortality from cancers other than breast cancer among the screened cases, 
(Skrabanek, 1988a; Tabár e/a/., 1988) but incomparability of patients in both 
groups due to lead-time and/or length-time and/or selection bias makes this 
result inconclusive (Anonymous, 1981). Aron and Prorok avoided these 
problems by defining a subset of breast cancer cases from the HIP-study which 
was unaffected by length-time and selection-bias, thanks to the ending of the 
project and by choosing the date of randomisation as starting date for survival 
analysis in order to avoid lead-time bias (Aron & Prorok, 1986). Survival 
curves related to deaths other than breast cancer for study and control breast 
cancer cases were not significantly different, although there was a slight 
tendency to excess deaths in the study breast cancer cases after 10 years of 
follow up. Unfortunately the proportion of deaths from other causes than 
breast cancer in this subpopulation was rather small. In the Malmö trial, 
women with breast cancer in both the study and control groups showed the 
same pattern of deaths from causes other than breast cancer in a follow-up of 
almost 9 years (Andersson et al,, 1988). 
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Furthermore, it could be doubted whether screening will reveal any long-term 
effects, since screening tends to detect a disproportionally great number of 
slowly growing tumours (length-time bias) (Cole & Morrison, 1980). Analysis 
of the HIP-data suggested a benefit of screening on breast cancer mortality 
extending over 15-18 years of follow-up (Shapiro et al., 1988). 
There is some discussion on whether the ultimate impact of screening will be 
as high as previously reported by the present screening projects, since there is 
evidence that currently diagnosed cancers are smaller than they used to be, 
even outside an organized screening programme (Day & Miller, 1988). It may 
be that in some countries tumour size already declined to such a favourable 
level that prognosis of breast cancer patients, currently diagnosed outside 
screening programmes, has already improved further, reducing the impact of 
screening. Prospective studies may show the consequence of this reduction in 
average tumour size on breast cancer mortality and screening effects. 
Unfavourable effects of screening 
Radiation risk 
When Bailar in 1976 suggested that radiation from mammography might 
induce breast cancer in large numbers of women, screening for breast cancer 
in the U.S. became very impopular (Bailar, 1976). Since then many studies 
about a potential radiation risk have been conducted (Beahrs et al., 1979; 
UNSCEAR, 1986; Boice et al., 1979; Barai étal., 1977; Gohagan étal., 1986; 
Gezondheidsraad 1987; Evans et al, 1986; Feig, 1988). The risk of radiation 
induced breast cancer is associated with age. Risk is greatest for women 
exposed as adolescents (UNSCEAR, 1986; Boice et a/, 1979) and may be 
lower for adult women (Barai et al, 1977). 
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Dosage levels of mammography dropped substantially since the HIP-study, 
where average skin dosage was 7.7 Rad (Boice, 1986). In the Breast Cancer 
Detection Demonstration Projects average surface exposure was 0.47 Rad for 
film screen and 1.2 Rad for xeromammography (Howard, 1987). With recent 
film screen methods average exposure for a two-view mammographical 
examination is about 0.12 Rad (Gohagan et ai, 1986). Life-time radiation 
doses to the breast from screening mammography will be between 1-2 Rad 
(Evans et a!., 1986). The estimated increased life-time risk of breast cancer 
from mammographie screening will be about 5 cases per 10,000 women 
(Boice, 1986), which is almost negligible in comparison with the natural risk 
of 1 of every 10 women ultimately having breast cancer (Feig, 1988). 
Mammographie screening radiation will increase a woman's life-time risk of 
breast cancer from 9.09 per cent to 9.14 per cent (Boice, 1986). Thus periodic 
screening of 10,000 women will increase the natural breast cancer incidence 
from 1,000 to about 1,005 (Gezondheidsraad, 1987). When viewed from a 
population perspective and applied to millions of women, this still means a 
substantial number of screening induced cases, even though these cases may 
have a favourable prognosis if detected in an early stage. 
'Unnecessary' biopsies 
Unnecessary biopsies may be defined as biopsies for a screen-detected suspect 
lesion which proves to be non-malignant. It is important to reduce the number 
of unnecessary biopsies as much as possible, since they lead to psychological 
distress among referred women (Fentiman, 1988) and cause high financial 
costs. 
The positive predictive value of biopsy (PV+), defined as the probability of 
having breast cancer diagnosis given a biopsy recommendation, is often mixed 
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up with the positive predictive value of referral which denotes the number of 
breast cancer patients diagnosed among all referrals. Since not all referred 
women are biopsied the PV+ for referral will be lower as compared to the 
PV+ for biopsy (Rombach, 1983). Furthermore, the PV+ for biopsy depends 
on the sensitivity and specificity of the screening test as well as on the 
prevalence of the disease (Vecchio, 1966). Therefore different PV+s for 
biopsy that are reported in screening programmes are difficult to compare. 
Prevalence of breast cancer varies geographically, and with other risk factors, 
such as age. Screening of a high risk group will always reveal relatively high 
PV+s and hence fewer unnecessary biopsies. Different screening intervals will 
also influence disease prevalence and thus biopsy-rates. Furthermore, validity 
of the test is dependent on viewing technique, mammographie equipment, 
experience and knowledge of the screening-team (Peeters et al., 1987) 
Predictive values of less than 20% were reported (Skrabanek, 1985a; Hall, 
1986) for programmes in the U.S.A. (Shaprio et al., 1966; Baker, 1982), 
Canada (Baines eia/., 1986) and London (Chamberlain, 1984). These PV+s 
can be explained partly from screening a population with a low disease 
prevalence and partly because of an aggressive referral procedure focussed on 
a high sensitivity (the latter enhanced by fear for claims of women with breast 
cancer after a preceding negative mammography) (Kopans & Swann, 1988). 
However, many screening programmes reported much higher PV+s, varying 
between 35-80% (Peeters etaL, 1987; Thomas et al., 1983; Andersson, 1979; 
Tabár & Gad, 1981; de Waard et al., 1984). The Swedish W&E trial, which 
established a 30% breast cancer mortality reduction in the study population 
(Tabár et al., 1985), reported a positive predictive value of 65% for biopsies 
(Tabár & Gad, 1981). Interpretation of the value of a high PV+ should also 
include consideration of the rate of interval cancers, since aiming for a high 
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PV+ by only referring women highly suspect for malignancy can cause a great 
number of interval cancers. In the Nijmegen programme the average interval 
cancer rate (with a screening interval of 2 years) was 1.00-1.27 per 1,000 
screened woman-years, while the average positive PV+s for referral and 
biopsy were 45% and 63%, respectively (Peelers eí al., 1988). 
Overdiagnosis 
Overdiagnosis is defined as the diagnosis and subsequent (unnecessary) 
treatment of breast cancer that is detected at screening but that would never 
have been detected (and treated) in a non-screening situation. Morrison has 
distinguished two kinds of overdiagnosis (Morrison, 1985). Breast cancer 
detected as a result of screening is diagnosed on average one to four years 
earlier than symptomatic cancer (Moskowitz, 1986; Walter & Day, 1983). 
This is called the lead-time period. All women who die from causes other than 
breast cancer during this lead-time period have their breast cancer 
'overdiagnosed'. Considering the short lead-time period, the proportion of 
overdiagnoses will be rather small except for women at very high age. With a 
computer simulated screening programme for women aged 50-70 years, 
screened with a 2-year interval, this form of overdiagnosis was calculated to 
be 3-4% (Ineveld et ai, 1988). 
The second type of overdiagnosis is due to the detection of so-called 'minimal' 
lesions, which would not have grown into an invasive stale and thus some of 
these cases would have remained undetected in a non-screening situation 
(Howard, 1987; Skrabanek, 1985). For instance, intraductal breast cancers 
constitute about 10-20% of all breast cancers detected in a screened population 
(Thomas et al., 1977; Schnitt étal, 1988), whereas this is only 3-5% in the 
non-screening setting (Rosen et a/, 1980; Rosner et al-, 1980). In some small 
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retrospective studies it was suggested that 30-70% of patients with an 
intraductal lesion treated by biopsy alone, locally had no evidence of the 
disease after a follow-up of 15-20 years (Rosen eia/, 1980; Rosner et al., 
1980; Betsill eia/., 1978; Page et al., 1982). 
Overdiagnosis and unnecessary subsequent treatment was also suggested by 
Greenberg and Stevens who showed that mastectomy-rates in the U.S. have 
been twice as high as in England. Rates had increased dramatically between 
1970-1975, at which time screening became popular in the U.S. (Skrabanek, 
1988a; Anonymous, 1981; Greenberg & Stevens, 1986). However, in the 
1960s in the U.S. surgical rates were already twice as high as in England in 
the 1960s, even before screening was widely accepted. The overall rate of 
surgical interventions (complete and partial mastectomy as well as biopsies) 
peaked in 1974/1975 but declined to the level of the earlier 1970s afterwards. 
To evaluate the possibility of overdiagnosis in such a trend study is very 
difficult, because of changes in coding systems, changes in treatment, etc. 
The extent to which overdiagnosis occurs, is to be evaluated in screening trials 
by analysing cases in intervention and control groups. In such a comparison 
cumulative numbers in both groups are easily misinterpreted because of the 
extra number of cases in the screening group resulting from an earlier date of 
diagnosis (Tabár et al., 1985; Verbeek étal., 1984; Skrabanek, 1985). There 
are two ways to overcome this. 
First, cumulative numbers of cases in study and control group should equalise 
after ending of a screening project, if there was no overdiagnosis. In the HIP-
study, the only programme known that had been ended, a similar cumulative 
incidence was shown in the study and control group 1-2 years after finishing, 
indicating there was no overdiagnosis in this project (Wright, 1986; 
Greenberg & Stevens, 1986; Shapiro et al, 1985). However, since the HIP 
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trial overdiagnosis is still a risk, since modem mammography has been 
further improved in detecting minimal cancers. A second way of analysing the 
extent of overdiagnosis is by comparing detection rates of breast cancer in 
study and control group after the beginning years of screening (excluding 
cancers detected at first screening). The W&E trial showed a higher incidence 
in the studygroup than in the controlgroup in women aged 40-49 at entry. The 
incidence rates for women aged 50-69 were similar in study and control group 
(Tabár et al., 1988). Incidence rates from the Nijmegen study for the period 
subsequent to the start of screening were compared to figures of a 
neighbouring city without screening (non-randomised). No excess incidence in 
the screened community was found (Peelers et al, 1988). However, in the 
UK-trial of early detection, the mean annual detection rate remained higher in 
the study centres than in the comparison centres even after exclusion of 
cancers detected at the first screening (UK trial of early detection of breast 
cancer group, 1988). Both the Nijmegen study (Peelers eia/., 1988) and the 
HIP-study (Aron & Prorok, 1986) showed an excess breast cancer detection in 
women aged 50-60 years at entry, whereas in the W&E trial an excess breast 
cancer was seen in women 40-49 years at entry. However, conclusions were 
impossible because of small numbers in each age-category, which makes it 
difficult to evaluate whether overdiagnosis, if any, was restricted to specific 
age-categories. 
There is another problem in diagnosing breast cancer, that has been critically 
discussed (Thier, 1977; Skrabanek, 1988b). Between normal and abnormal, 
cellular changes constitute a continuous spectrum without a distinct boundary 
between non-malignant and malignant. This may lead to a discrepancy in 
diagnosis. Of 506 intraductal lesions or small tumours in the BCDDP, 66 were 
thought to be benign or Tjorderline' at first histological review (Beahrs et a/., 
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1979). After a second review of all histological and clinical data only 7 
questionable cases remained (Beahrs & Smart, 1979). New diagnostic tools 
that advance the date of diagnosis will inevitably reveal unfamiliar lesions. 
Uncertainty regarding the biological behaviour of these lesions is not unusual 
and only thorough research can lead to a better understanding of the biologic 
nature of these lesions. 
interval cancers 
Interval cancers are defined as breast cancers diagnosed after a negative 
screening examination during the interval of the subsequent regular screening 
examination. The survival of women with interval cancer seems to be equal to 
the survival of breast cancer cases in the non-screening situation (Shapiro et 
al., 1982; Holmberg, 1986; Peeters et al., 1988). Interval cancer cases, 
diagnosed in the Malmö trial, however, showed a worse survival when 
compared with control patients, 'indicating that interval cancers were more 
malignant stage for stage. The Malmö trial used a screening interval of 18-24 
months, while in the W&E trial the interval was 24-36 months, which might 
be a reason for the more malignant type of interval cancers diagnosed in the 
Malmö trial. 
The number of interval cancers is strongly related to the length of the 
screening interval and to the age of the women participating. For instance 
between screen-detected and interval cancer cases the ratio was about 1:1 for 
women aged 50 or younger and about 3:1 for women aged 50 and over during 
two years of follow-up after screening (Peeters et al, 1988). For this reason it 
was propagated that screening should be done more frequently in younger 
women to be effective (Tabár eia/., 1987; Moskowitz, 1986). 
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The occurrence of interval cancers may be due to errors in the screening 
procedure (false-negatives). About one third of interval cancers were missed 
at previous mammography due to technical or observer errors (Frisell et al., 
1988; Martin et al., 1979; Peeters et ai, 1988; Rosen et ai., 1985;). There was 
no indication that this number declined in the course of the screening 
programme (Peeters et ai., 1988). Another reason for missing breast cancer at 
screening are radiographically occult tumours. About 15% of interval cancers 
were radiographically occult even at the time of diagnosis (Peeters et al., 
1988), while only 5-7% of breast cancer patients in a non-screening setting 
had negative diagnostic mammograms (Bums etaL, 1979; Cahill eia/., 1981). 
Radiographically occult tumours occurred more frequently in younger 
women. Histologically they were mainly intraductal cancers (ductal carcinoma 
in situ) or lobular invasive cancers. Without calcifications these types of breast 
cancers seem to be undectectable in dense breast tissue (Peelers et ai., 1988; 
Holland etaL, 1983)· 
Of all interval cancers 50% were either completely masked at the previous 
screening examination, or were newly grown since, which implies a high 
growth rate for this latter subset of interval cancers (Peeters et ai., 1988; 
Frisell et al., 1988). Probably only (part of) this subset of interval cancers 
would benefit from a screening programme with examinations at a shorter 
than 2 year time interval. 
No information is available on the question whether women (and physicians) 
tend to ignore symptoms subsequent to a negative screening examination and 
thus delay diagnosis. In practice, every woman with breast symptoms even 
when found negative at a recent screening should be reexamined carefully for 
cancer. And since interval cancers considerably influence the effectiveness of a 
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screening programme, it is imperative to aim for as high a sensitivity rate of 
mammography as possible, 
Conclusions 
Medical literature quite convincingly demonstrates screening with 
mammography to be effective in reducing breast cancer mortality in women 
aged 50 or over. Therefore it seems reasonable to screen this age-group. 
However, to balance the benefits of screening against the unfavourable effects 
several issues have to be closely monitored. 
The predictive value may be around 30% in the beginning period of 
screening, because screening of prevalence is conducted. However, it seems 
reasonable when screening of incidence is performed, to aim for a screening 
test with a positive predictive value for referral as high as 60-70%. In this 
way an even higher predictive value for biopsy is achieved, resulting in an 
acceptable number of unnecessary biopsies. To maintain such high figures of 
predictive values, at a constant rate of interval cancers, thorough training of 
radiographers, radiologists, pathologists and surgeons in the diagnosis and 
treatment of breast cancer is required (Witcombe, 1988; European Group for 
breast cancer screening, 1988a, 1988b; Working party on breast cancer 
screening, 1986; Warren R, 1988; Donovan eia/., 1988). 
With modem mammography the risk of inducing breast cancer by radiation 
seems negligible. Mammography will detect an important number of early 
lesions, which is the aim of screening, but contains the seeds of potential 
problems since overdiagnosis and subsequent unnecessary treatment may result 
from it. More well-designed follow-up studies and histological evaluation are 
needed to examine the natural course of these lesions. 
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The effect of screening was established in programmes with a two-year 
interval between screening. For women over 50 years of age at entry this 
interval seems correct. Close observation of the number of interval cancers is 
required to maintain the quality of screening. 
Further research about breast cancer mortality reduction, as well as in more 
aggressive and/or more frequent screening (and consequently radiation risk) 
in the age-group under 50 is necessary. The observation of the extent of long-
term effects of screening for all ages is required, since it is generally known 
that breast cancer can still kill after a long time (Hibberd et al., 1983; Al-
Fouadí eia/., 1987). 
Advantages and disadvantages of breast cancer should be weighed against 
financial costs (Knox et al., 1988). It is evident that screening will hardly 
improve life-expectancy of the total female population, but it will lengthen the 
lives of many breast cancer patients considerably. 
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SUMMARY 
In 1975 a population-based screening programme for breast cancer was 
initiated in Nijmegen. All women bom in the period 1910-1939 were invited 
for a mammographie examination every two years. The attendance rate for 
the first screening round in 1975/76 was 85%. In 1977/78 all women bom 
before 1940 (including the <1910 birth cohort) were invited, which caused 
the attendance rate to drop to 65%. Attendance declined further to a rate of 
50% in 1985/86, mainly because of ageing of the invited cohort. Detection in 
each screening round was on average 4 per 1,000 screened women, while the 
interval cancer rate remained fairly stable after each round: 1.6 per 1,000 
screened women in two years. 
Within this population the extent of side-effects of population screening has 
been studied. The main issues were false-positive screening test results, 
overdiagnosis and the occurrence of interval cancers. 
The predictive value of a positive screening mammography and of biopsy 
recommendation for women younger than 50 years, were 16-26% and 25-
40%, respectively. The predictive values were 34-57% and 58-90% 
respectively for women aged 50 or over. It turned out that it was impossible 
to reduce the number of false-positive mammographies through the use of 
information about risk factors, such as Wolfe classification, Quételet index or 
parity without increasing the number of false-negative cancers considerably. 
Follow-up of on average 5 years of women with a referral for clinical 
examination, but without a diagnosis of breast cancer, showed a 2-3 times as 
high a risk for breast cancer in this group when compared with women who 
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were never referred for clinical examination. However, the reason for this 
turned out to be a lack of experience in the correct work-up after referral. 
A false-positive referral may cause feelings that are rather positive based on 
coping skills within the first year of referral, but it may cause psychological 
distress in the long ran. However, firm conclusions cannot be based on this 
pilot study conducted in Nijmegen, 10 years after the start of the programme. 
The numbers of participating women who had, recently been faced with a 
false-positive result were very small (л= 10). 
There were no indications in the Nijmegen programme of an important extent 
of overdiagnosis of breast cancer, since the incidence rates after the beginning 
years of screening in Nijmegen proved to be comparable with those in 
Arnhem, where no screening programme was established. 
Breast cancers, occurring between two consecutive screening examinations are 
called interval cancers. Of 158 interval cancers occurring in five 
interscreening periods in the Nijmegen programme a quarter were missed at a 
previous exam, one sixth were radiologically occult even at the time of 
diagnosis and the remaining cases (60%) were 'true' interval cancers. Interval 
cancers of the latter group either were masked for some reason at the 
preceding examination or had newly reached a detectable stage. The 7-year 
overall survival of patients with a 'true' interval cancer was 72% and as such 
comparable with the survival of breast cancer patients diagnosed in a non-
screening setting. 60% of all interval cancers would probably not have been 
prevented by annual instead of 2-yearly screening examinations. 
Medical literature has quite convincingly demonstrated screening with 
mammography to be effective in reducing breast cancer mortality in women 
aged over 50. The disadvantages of screening, such as the occurrence of 
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unnecessary biopsies, or overdiagnosis and subsequent unnecessary treatment 
of breast cancer, or the occurrence of interval cancers should be minimized by 
adequate teaching of the screening and diagnostic team, by prospective studies 
on the natural course of minimal lesions and by the development of new 
(imaging) techniques of examining mammary tissue. 
Screening will considerably improve the life-expectancy of most breast cancer 
patients over age 50, at the cost of disadvantages of the other screenees. 
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SAMENVATTING 
In 1975 werd in Nijmegen een proefbevolkingsonderzoek gestart naar de 
vroege detectie van borstkanker. Hiervoor werden iedere 2 jaar alle vrouwen, 
die geboren zijn tussen 1910 en 1940 uitgenodigd voor een mammografisch 
onderzoek. De opkomst in de eerste screeningsronde in 1975/1976 was 85%. 
In 1977/1978 werden alle vrouwen geboren vóór 1940 (inclusief het geboorte 
cohort <1910) uitgenodigd, hetgeen een daling in de opkomst tot gevolg had 
naar 65%. De opkomst daalde verder naar 50% in 1985/1986, voornamelijk 
doordat de uitgenodigde groep vrouwen verouderde. De detektie van 
borstkanker in iedere screeningsronde was gemiddeld 4 per 1000 onderzochte 
vrouwen, terwijl het aantal interval carcinomen, dat in 2 jaar na iedere 
screeningsronde optrad, vrijwel constant bleef: 1,6 per 1000 gescreende 
vrouwen. 
Binnen dit proefbevolkingsonderzoek werden neveneffecten van screening 
bestudeerd, alsmede de mate waarin deze neveneffecten optraden. De 
belangrijkste punten hierbij waren fout-positieve mammografische 
screeningsuitslagen, de evaluatie van mogelijke overdiagnose en het optreden 
van borstkanker tussen twee opeen volgende screeningsonderzoeken 
(intervalcarcinomen). 
De voorspellende waarde van een positief bevonden screeningsmammogram 
en van een biopsie waren respectievelijk 16-26% en 25-40% voor vrouwen 
jonger dan 50 jaar. Voor vrouwen 50 jaar of ouder waren deze waardes 
respectievelijk 34-57% en 58-90%. Het was onmogelijk het aantal fout-
positieve mammografische testuitslagen te reduceren, door gebruik te maken 
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van informatie over risicofactoren, als Wolfe classificatie, Quételet index of 
pariteit. 
Follow-up van gemiddeld 5 jaar van vrouwen met een advies voor klinisch 
onderzoek, dat niet resulteerde in een diagnose van borstkanker, toonde een 2-
3 keer verhoogd risiko op borstkanker aan in deze groep vrouwen, vergeleken 
met vrouwen die nooit een advies hadden gekregen voor klinisch onderzoek. 
De reden hiervoor bleek een incorrecte diagnostiek na de doorverwijzing te 
zijn tgv een gebrek in ervaring met de diagnostiek van vroege afwijkingen. 
Het eerste jaar na een 'onterechte' doorverwijzing zouden vrouwen 
verdringingsmechanismen kunnen vertonen die op de lange termijn tot 
psychologische stress zouden kunnen leiden. Deze conclusies waren echter op 
basis van het geringe aantal participerende vrouwen (л = 10) niet te trekken. 
Er was geen indicatie van een belangrijke mate van overdiagnose in het 
Nijmeegse project, omdat de incidentie van borstkanker na de beginjaren van 
screenen in Nijmegen gelijk was aan die in Arnhem, waar geen screening 
plaats vond. 
Van alle intervalcarcinomen, die tussen twee opeenvolgende screeningsronden 
gediagnostiseerd werden (158 in 5 'inter'-screeningsperioden in Nijmegen), 
bleek bij revisie 1/4 gemist tijdens het voorgaande screeningsonderzoek, 1/6 
was radiologisch occult zelfs bij diagnose en was de rest (60%) "echt" 
intervalcarcinoom. Carcinomen, behorende tot deze laatste groep waren ofwel 
gemaskeerd bij een eerder onderzoek of sindsdien nieuw gegroeid tot een 
detecteerbare fase. De totale 7-jaars overleving voor vrouwen met een 'echt' 
intervalcarcinoom was 72% en vergelijkbaar met de overleving van vrouwen 
met borstkanker, gediagnostiseerd buiten een screeningsonderzoek. Bij 
verkorting van het screeningsinterval van 2 naar 1 jaar zou waarschijnlijk 
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60% van de huidige intervalcarcinomen nog steeds gediagnostiseerd worden 
tussen twee opeenvolgende screeningsonderzoeken. 
De medische literatuur is vrij eensluidend over een positief effect van screenen 
met behulp van mammografie in het reduceren van de borstkankersterfte voor 
vrouwen ouder dan 50 jaar. De nadelen van screening, zoals een hoog aantal 
onnodige biopsiën, het optreden van overdiagnose, of het optreden van 
interval carcinomen moet geminimaliseerd worden door middel van adequate 
scholing van het screening team, door toekomstig onderzoek naar het 
natuurlijk beloop van minimale afwijkingen en door het zoeken naar nieuwe 
(röntgenologische) technieken voor borstonderzoek. 
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1. Het advies van de Gezondheidsraad om screening op borstkanker niet uit 
te voeren bij vrouwen boven de 70 jaar is niet gebaseerd op wetenschap­
pelijk onderzoek. 
(Gezondheidsraad, 1987: Vroege opsporing borstkanker, advies uitge­
bracht door een commissie van de Gezondheidsraad.) 
2. Door vergroting van hun epidemiologische kennis zal de term Tout-
positieve mammografische screenings-uitslag' bij specialisten minder 
beladen overkomen. 
3. Specifieke opleiding van radiodiagnostisch laboranten, radiologen en 
patholoog-anatomen, betrokken bij het bevolkingsonderzoek borstkanker 
is noodzakelijk om kwaliteit van screening te bereiken en te waarborgen. 
4. Het belangrijkste kriterium van 'Wilson en Jungner', namelijk het effekt 
van screening, in de zin van een mortaliteitsdaling, is het beste te onder­
zoeken middels een gerandomiseerd proefbevolkingsonderzoek. 
5. Thermonucleaire wapens dienen te worden gebruikt om het leven van de 
stervende zon, geschatte levensverwachting 5 miljard jaar, te verlengen. 
(Reeves H. De evolutie van het heelal. Van Gennip Amsterdam 1988; 
ρ 138.) 
6. De uitdijing van het heelal is af te leiden uit het feit dat het 's nachts 
donker is. 
(Hawking S. Het heelal. Verleden en toekomst van ruimte en tijd. Uitge­
verij Bert Bakker Amsterdam 1988; ρ 17. Reeves Η. De evolutie van het 
heelal. Van Gennip Amsterdam 1988; ρ 62.) 
7. Het leveren van medische apparatuur aan Derde Wereldlanden levert geen 
bijdrage aan de verbetering van de gezondheidssituatie in deze landen. 
(Hoebink PRJ. Geven is nemen: de Nederlandse ontwikkelingshulp aan 
Tanzania en Sri Lanka. Stichting Derde Wereld Publikaties Nijmegen 
1988; ρ 177.) 
8. Dat het bedrijven van klinisch-wetenschappelijk onderzoek net zo moeilijk 
is als het zoeken naar de speld in een hooiberg, blijkt uit een recent 
gepubliceerd artikel, waarin de auteur de klinisch-wetenschappelijk 
onderzoeker vergelijkt met iemand die 's avonds zijn op het strand 
zoekgeraakt horloge gaat zoeken. 
(Vandenbroucke JP. Een recept voor een klinisch-wetenschappelijk 
leeronderzoek. Ned Tijdschr Geneeskd 1989; 133, 34.) 
9. De gemiddelde lengtetoename van de mens in de afgelopen decennia kan 
in het licht van de evolutie een voorbode zijn van het uitsterven van deze 
soort. 
(Groenewoud JMM. Persoonlijke mededeling. ) 
10. En als u nu een grappige stelling verwacht, dan komt u aardig op de 
koffie. 
Stellingen behorende bij het proefschrift van Petra Peeters: The extent of side-
effects in screening for breast cancer. An epidemiological evaluation of the 
Nijmegen project, 1975-1986. Nijmegen, 6 april 1989. 


